CN112574255B - Organic arsine-based CDK inhibitor and preparation method and application thereof - Google Patents
Organic arsine-based CDK inhibitor and preparation method and application thereof Download PDFInfo
- Publication number
- CN112574255B CN112574255B CN201910925781.8A CN201910925781A CN112574255B CN 112574255 B CN112574255 B CN 112574255B CN 201910925781 A CN201910925781 A CN 201910925781A CN 112574255 B CN112574255 B CN 112574255B
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- group
- zsq
- mmol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title abstract description 19
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 title abstract description 11
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 247
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- -1 pyrazolopyrimidinyl Chemical group 0.000 claims description 70
- 230000000694 effects Effects 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims description 35
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 102100038114 Cyclin-dependent kinase 13 Human genes 0.000 claims description 9
- 101000884348 Homo sapiens Cyclin-dependent kinase 13 Proteins 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000012453 solvate Substances 0.000 abstract description 12
- 150000004677 hydrates Chemical class 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 102
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- 230000015572 biosynthetic process Effects 0.000 description 96
- 238000003786 synthesis reaction Methods 0.000 description 95
- 238000004440 column chromatography Methods 0.000 description 78
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 72
- 239000007787 solid Substances 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 71
- 238000006243 chemical reaction Methods 0.000 description 69
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 51
- 239000000203 mixture Substances 0.000 description 50
- 239000011259 mixed solution Substances 0.000 description 49
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 46
- 239000011541 reaction mixture Substances 0.000 description 44
- 108091000080 Phosphotransferase Proteins 0.000 description 43
- 239000012074 organic phase Substances 0.000 description 43
- 102000020233 phosphotransferase Human genes 0.000 description 43
- 239000012071 phase Substances 0.000 description 42
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 40
- 230000002441 reversible effect Effects 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 36
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 36
- 239000000843 powder Substances 0.000 description 35
- 239000004698 Polyethylene Substances 0.000 description 33
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 33
- 239000000741 silica gel Substances 0.000 description 32
- 229910002027 silica gel Inorganic materials 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- 238000003756 stirring Methods 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 230000026731 phosphorylation Effects 0.000 description 19
- 238000006366 phosphorylation reaction Methods 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000005842 heteroatom Chemical group 0.000 description 18
- 229910052717 sulfur Inorganic materials 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- OBJNFLYHUXWUPF-IZZDOVSWSA-N n-[3-[[5-chloro-4-(1h-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(e)-4-(dimethylamino)but-2-enoyl]amino]benzamide Chemical compound C1=CC(NC(=O)/C=C/CN(C)C)=CC=C1C(=O)NC1=CC=CC(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)=C1 OBJNFLYHUXWUPF-IZZDOVSWSA-N 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- RUBYHLPRZRMTJO-MOVYNIQHSA-N THZ531 Chemical compound c1cc(NC(=O)/C=C/CN(C)C)ccc1C(=O)N1CCC[C@@H](Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc32)C1 RUBYHLPRZRMTJO-MOVYNIQHSA-N 0.000 description 13
- VJWWIRSVNSXUAC-UHFFFAOYSA-N arsinic acid Chemical compound O[AsH2]=O VJWWIRSVNSXUAC-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 108091007914 CDKs Proteins 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 229960002685 biotin Drugs 0.000 description 9
- 239000011616 biotin Substances 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- KBYOBAICCHNMNJ-UHFFFAOYSA-L diperchloryloxymercury Chemical compound [Hg+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O KBYOBAICCHNMNJ-UHFFFAOYSA-L 0.000 description 9
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010041067 Small cell lung cancer Diseases 0.000 description 6
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 101100495324 Caenorhabditis elegans cdk-7 gene Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 230000005971 DNA damage repair Effects 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- NDLAWHCITGPRJY-UHFFFAOYSA-M O.O.O.Cl(=O)(=O)(=O)[O-].[Hg+] Chemical compound O.O.O.Cl(=O)(=O)(=O)[O-].[Hg+] NDLAWHCITGPRJY-UHFFFAOYSA-M 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- SCJNYBYSTCRPAO-LXBQGUBHSA-N CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 Chemical compound CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 SCJNYBYSTCRPAO-LXBQGUBHSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 102000009572 RNA Polymerase II Human genes 0.000 description 3
- 108010009460 RNA Polymerase II Proteins 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 2
- MQNHKLMHRZYTBZ-UHFFFAOYSA-N 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C(O)=O)=C1 MQNHKLMHRZYTBZ-UHFFFAOYSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101100327354 Caenorhabditis elegans cdk-12 gene Proteins 0.000 description 2
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282421 Canidae Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QXAITBQSYVNQDR-ZIOPAAQOSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1/N=C/N(C)\C=N\C1=CC=C(C)C=C1C QXAITBQSYVNQDR-ZIOPAAQOSA-N 0.000 description 2
- 229960002587 amitraz Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 2
- 229960001420 nimustine Drugs 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
- 229940067157 phenylhydrazine Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- WPWXYQIMXTUMJB-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CN)C1 WPWXYQIMXTUMJB-UHFFFAOYSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 108010002164 tyrosine receptor Proteins 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- DSCFFEYYQKSRSV-FEPQRWDDSA-N (-)-Quebrachitol Natural products COC1[C@@H](O)[C@@H](O)C(O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-FEPQRWDDSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RNXVXXXZBIXZMS-UHFFFAOYSA-N (4-aminophenyl)arsinic acid Chemical compound NC1=CC=C([AsH](O)=O)C=C1 RNXVXXXZBIXZMS-UHFFFAOYSA-N 0.000 description 1
- QYTBUHYLQBWDSV-UHFFFAOYSA-N (4-hydroxy-3-nitrophenyl)arsinic acid Chemical compound OC1=C(C=C(C=C1)[AsH](O)=O)[N+]([O-])=O QYTBUHYLQBWDSV-UHFFFAOYSA-N 0.000 description 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- ZSDGZYGEBQECGY-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-(2,5-dichloropyrimidin-4-yl)indole Chemical compound ClC1=NC=C(Cl)C(C=2C3=CC=CC=C3N(C=2)S(=O)(=O)C=2C=CC=CC=2)=N1 ZSDGZYGEBQECGY-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- WRFYXBKJHZAUTO-UHFFFAOYSA-N 1-nitro-2-propan-2-ylsulfanylbenzene Chemical compound CC(C)SC1=CC=CC=C1[N+]([O-])=O WRFYXBKJHZAUTO-UHFFFAOYSA-N 0.000 description 1
- GBFWDLQEEMHXME-UHFFFAOYSA-N 1-nitro-2-propan-2-ylsulfonylbenzene Chemical compound CC(C)S(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GBFWDLQEEMHXME-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- DSCFFEYYQKSRSV-GWJPIIGYSA-N 1D-5-O-methyl-myo-inositol Chemical compound CO[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-GWJPIIGYSA-N 0.000 description 1
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 1
- RGJNPJRAXMSHKN-UHFFFAOYSA-N 2,4-dichloro-5-iodopyrimidine Chemical compound ClC1=NC=C(I)C(Cl)=N1 RGJNPJRAXMSHKN-UHFFFAOYSA-N 0.000 description 1
- UKPGBQWHGNDSMU-UHFFFAOYSA-N 2-[1-(7-amino-3-ethylpyrazolo[1,5-a]pyrimidin-5-yl)piperidin-2-yl]ethanol Chemical compound CCC1=C2N=C(C=C(N)N2N=C1)N1CCCCC1CCO UKPGBQWHGNDSMU-UHFFFAOYSA-N 0.000 description 1
- RGLDALVJLSFYMV-UHFFFAOYSA-N 2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]acetic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(CC(O)=O)=C1 RGLDALVJLSFYMV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WBMMJHMFZQJKNC-UHFFFAOYSA-N 2-formyl-3-methylbutanenitrile Chemical compound CC(C)C(C=O)C#N WBMMJHMFZQJKNC-UHFFFAOYSA-N 0.000 description 1
- CWNRYVQFAMHXLM-UHFFFAOYSA-N 2-formylbutanenitrile Chemical compound CCC(C=O)C#N CWNRYVQFAMHXLM-UHFFFAOYSA-N 0.000 description 1
- PTHDBHDZSMGHKF-UHFFFAOYSA-N 2-piperidin-2-ylethanol Chemical compound OCCC1CCCCN1 PTHDBHDZSMGHKF-UHFFFAOYSA-N 0.000 description 1
- GMLAMRMKROYXNZ-UHFFFAOYSA-N 2-propan-2-ylsulfonylaniline Chemical compound CC(C)S(=O)(=O)C1=CC=CC=C1N GMLAMRMKROYXNZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- FBEYVYDAVBOFOJ-UHFFFAOYSA-N 3-(2,5-dichloropyrimidin-4-yl)-1h-indole Chemical compound ClC1=NC=C(Cl)C(C=2C3=CC=CC=C3NC=2)=N1 FBEYVYDAVBOFOJ-UHFFFAOYSA-N 0.000 description 1
- BAYIBFKTYRYJLJ-UHFFFAOYSA-N 3-(2-chloro-5-iodopyrimidin-4-yl)-1H-indole Chemical compound ClC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)I BAYIBFKTYRYJLJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- JJLAWXZOOBEXDO-UHFFFAOYSA-N 3-ethyl-7-hydroxy-4H-pyrazolo[1,5-a]pyrimidin-5-one Chemical compound CCc1cnn2c(O)cc(=O)[nH]c12 JJLAWXZOOBEXDO-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZAXXYZNORCVGRU-UHFFFAOYSA-N 4-[1-(benzenesulfonyl)indol-3-yl]-5-chloro-N-(piperidin-3-ylmethyl)pyrimidin-2-amine Chemical compound Clc1cnc(NCC2CCCNC2)nc1-c1cn(c2ccccc12)S(=O)(=O)c1ccccc1 ZAXXYZNORCVGRU-UHFFFAOYSA-N 0.000 description 1
- YNDNKBDMUZSQIV-MRXNPFEDSA-N 4-[1-(benzenesulfonyl)indol-3-yl]-5-chloro-N-[(3R)-piperidin-3-yl]pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC1)N[C@H]1CNCCC1)C1=CN(C2=CC=CC=C12)S(=O)(=O)C1=CC=CC=C1 YNDNKBDMUZSQIV-MRXNPFEDSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- RDCODVKTTJWFAR-UHFFFAOYSA-N 4-ethyl-1h-pyrazol-5-amine Chemical compound CCC=1C=NNC=1N RDCODVKTTJWFAR-UHFFFAOYSA-N 0.000 description 1
- UQTLFNBARWAWIS-UHFFFAOYSA-N 4-propan-2-yl-1h-pyrazol-5-amine Chemical compound CC(C)C=1C=NNC=1N UQTLFNBARWAWIS-UHFFFAOYSA-N 0.000 description 1
- QFSOXHZZXZVMHY-UHFFFAOYSA-N 5,7-dichloro-3-ethylpyrazolo[1,5-a]pyrimidine Chemical compound ClC1=CC(Cl)=NC2=C(CC)C=NN21 QFSOXHZZXZVMHY-UHFFFAOYSA-N 0.000 description 1
- VAAJGCDAYQIYPO-UHFFFAOYSA-N 5,7-dichloro-3-propan-2-ylpyrazolo[1,5-a]pyrimidine Chemical compound ClC1=CC(Cl)=NC2=C(C(C)C)C=NN21 VAAJGCDAYQIYPO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WEBRPPNFAKIURK-UHFFFAOYSA-N 7-hydroxy-3-propan-2-yl-4H-pyrazolo[1,5-a]pyrimidin-5-one Chemical compound OC1=CC(O)=NC2=C(C(C)C)C=NN21 WEBRPPNFAKIURK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- NTYXNTSPCWMMHA-LJQANCHMSA-N C#CC1=CN=C(N[C@H]2CNCCC2)N=C1C(C1=CC=CC=C11)=CN1S(C1=CC=CC=C1)(=O)=O Chemical compound C#CC1=CN=C(N[C@H]2CNCCC2)N=C1C(C1=CC=CC=C11)=CN1S(C1=CC=CC=C1)(=O)=O NTYXNTSPCWMMHA-LJQANCHMSA-N 0.000 description 1
- HVPAERPIODSNPK-QGZVFWFLSA-N C(C1=CC=CC=C1)NC1=CC(=NC=2N1N=CC=2C(C)C)N[C@H]1CNCCC1 Chemical compound C(C1=CC=CC=C1)NC1=CC(=NC=2N1N=CC=2C(C)C)N[C@H]1CNCCC1 HVPAERPIODSNPK-QGZVFWFLSA-N 0.000 description 1
- XOKFNTNCMZAUKY-UHFFFAOYSA-N CC(C)C1=C2N=C(C=C(N2N=C1)N(CC3=CC=CC=C3)C(=O)OC(C)(C)C)NCC4=CC(=CC=C4)C(=O)O Chemical compound CC(C)C1=C2N=C(C=C(N2N=C1)N(CC3=CC=CC=C3)C(=O)OC(C)(C)C)NCC4=CC(=CC=C4)C(=O)O XOKFNTNCMZAUKY-UHFFFAOYSA-N 0.000 description 1
- DZXYHXGDXOQMAD-QGZVFWFLSA-N CC(C)C1=C2N=C(C=C(N2N=C1)N[C@@H]3CCCNC3)NCC4=CC=CC=C4 Chemical compound CC(C)C1=C2N=C(C=C(N2N=C1)N[C@@H]3CCCNC3)NCC4=CC=CC=C4 DZXYHXGDXOQMAD-QGZVFWFLSA-N 0.000 description 1
- HSTKMAMIXVNGKU-UHFFFAOYSA-N CCC1=C2N=C(C=C(N2N=C1)NCC3=CC=C(C=C3)OC)Cl Chemical compound CCC1=C2N=C(C=C(N2N=C1)NCC3=CC=C(C=C3)OC)Cl HSTKMAMIXVNGKU-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- FUMZBMVZRXTLFS-UHFFFAOYSA-N C[Si](C)(C)C#CC(C(C(C1=CC=CC=C11)=CN1S(C1=CC=CC=C1)(=O)=O)=N1)=CN=C1Cl Chemical compound C[Si](C)(C)C#CC(C(C(C1=CC=CC=C11)=CN1S(C1=CC=CC=C1)(=O)=O)=N1)=CN=C1Cl FUMZBMVZRXTLFS-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PPKJGSBBVLNQIT-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)S(=O)(=O)C1=CC=CC=C1)I Chemical compound ClC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)S(=O)(=O)C1=CC=CC=C1)I PPKJGSBBVLNQIT-UHFFFAOYSA-N 0.000 description 1
- FPZZWAVDOQUIAK-CYBMUJFWSA-N ClC=1C(=NC(=NC=1)N[C@H]1CNCCC1)NC1=C(C=CC=C1)S(=O)(=O)C(C)C Chemical compound ClC=1C(=NC(=NC=1)N[C@H]1CNCCC1)NC1=C(C=CC=C1)S(=O)(=O)C(C)C FPZZWAVDOQUIAK-CYBMUJFWSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 101000628578 Homo sapiens Serine/threonine-protein kinase 16 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001425800 Pipa Species 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 229940123752 RNA synthesis inhibitor Drugs 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100026758 Serine/threonine-protein kinase 16 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- XKNKHVGWJDPIRJ-UHFFFAOYSA-N arsanilic acid Chemical compound NC1=CC=C([As](O)(O)=O)C=C1 XKNKHVGWJDPIRJ-UHFFFAOYSA-N 0.000 description 1
- GCPXMJHSNVMWNM-UHFFFAOYSA-N arsenous acid Chemical group O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- HAXSCOGBPLMKKV-UHFFFAOYSA-N benzene;1h-indole Chemical group C1=CC=CC=C1.C1=CC=C2NC=CC2=C1 HAXSCOGBPLMKKV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- BYBCIJRHVGNOPT-UHFFFAOYSA-N benzyl 3-(aminomethyl)benzoate Chemical compound NCC1=CC=CC(C(=O)OCC=2C=CC=CC=2)=C1 BYBCIJRHVGNOPT-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229940125808 covalent inhibitor Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- QHDRKFYEGYYIIK-UHFFFAOYSA-N isovaleronitrile Chemical compound CC(C)CC#N QHDRKFYEGYYIIK-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DPLYAMCNFUJBLH-UHFFFAOYSA-N n-benzyl-5-chloro-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C=1C(Cl)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 DPLYAMCNFUJBLH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical compound OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- KCVVEIFZXCXRJG-UHFFFAOYSA-N tert-butyl n-benzyl-n-(5-chloro-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl)carbamate Chemical compound C=1C(Cl)=NC2=C(C(C)C)C=NN2C=1N(C(=O)OC(C)(C)C)CC1=CC=CC=C1 KCVVEIFZXCXRJG-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/80—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/74—Aromatic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/74—Aromatic compounds
- C07F9/76—Aromatic compounds containing hydroxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an organic arsine-based CDK inhibitor, and a preparation method and application thereof. In particular, compounds of formula I, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, hydrates or solvates thereof, are provided; and the preparation method and application thereof, wherein the definition of each group in the formula is shown in the specification.
Description
Technical Field
The invention belongs to the field of medicines, and in particular relates to an organic arsine-based cell Cycle Dependent Kinase (CDK) inhibitor, a preparation method and application thereof.
Background
In the past twenty years, the development and application of targeted drugs have also been well-developed while chemotherapeutic drugs have been widely used in cancer research. Of the various proteins closely related to carcinogenesis and exacerbation, several members of the kinase protein family have been identified as effective therapeutic targets, and tens of targeted kinase inhibitors have also been approved for cancer treatment.
In 2014, gray et al reported that the first covalent inhibitor of CDK7, THZ1, was developed based on cysteine residue Cys312 on the C-terminal motif outside the ATP binding pocket of the CDK7 kinase domain, using a substituted acrylamide as electrophilic group. In addition to inhibiting CDK7, THZ1 also inhibits CDK12/13, which has a cysteine-like residue. Through inhibiting CDK7/12/13, THZ1 can effectively inhibit the activation of RNA polymerase II at low concentration, further inhibit the transcription initiation of superregulators in cancer cells, finally effectively inhibit the growth of the cancer cells, and has good curative effects in various tumor models such as T cell acute lymphoblastic leukemia (T-ALL), small Cell Lung Cancer (SCLC), neuroblastoma, triple negative breast cancer and the like. However, THZ1 has significant off-target effects and its pharmacokinetic properties are also not ideal.
In 2016 Gray et al developed a highly specific CDK12/13 inhibitor THZ531 based on THZ1, which was able to specifically induce apoptosis in some tumor cells, but which still had pharmacokinetic disadvantages including, for example, low bioavailability, short half-life, etc.
Syros improves on the basis of THZ1 to obtain SY-1365 with better specificity, and is currently in the first stage of clinical trials for treating solid tumors. Limitations in drug substitution properties have led to SY-1365 being administered by intravenous injection.
Accordingly, there is a great need in the art to provide CDK inhibitors that are highly selective, highly safe, and/or have better pharmacokinetic properties.
Disclosure of Invention
It is an object of the present invention to provide CDK inhibitors that are highly selective, highly safe, and/or have better pharmacokinetic properties. The inhibitors of the invention are a class of organic arsine based CDK inhibitors.
In a first aspect of the invention, there is provided a compound of formula I, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof;
Wherein,
Each X 1、X2 is independently selected from the group consisting of: none, O, S, NR 8、CH2;
R 8 is selected from the group consisting of: H. a substituted or unsubstituted C1-C6 alkyl group;
R 1、R2 are each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, -CO-Rd, wherein Rd is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl; or R 1、R2 taken together with the adjacent X 1、X2 and As forms a substituted or unsubstituted 4 to 8 membered heterocyclic ring containing one As heteroatom and 0-3 heteroatoms selected from N, O and S;
R 3 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C10 cycloalkyl;
n 1 is 0,1, 2,3 or 4;
Each R 4 is independently selected from: H. d, OH, amino, nitro, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C10 cycloalkyl;
L 1、L2 and L 3 are each independently selected from the group consisting of: none, - (Z) m-; and L 1 and L 2 are not both absent; wherein each Z is independently selected from: C1-C6 alkylene, -NR 6-,-NR6-R7 -, -O-, -CO-, m is 1, 2, 3 or 4;
Each R 6 is independently selected from the group consisting of: H. a substituted or unsubstituted C1-C4 alkyl group;
r 7 is a substituted or unsubstituted C1-C8 alkylene group;
A is selected from the group consisting of: an unsubstituted, substituted or unsubstituted C6-C10 aryl, a substituted or unsubstituted 5-10 membered heteroaryl, a substituted or unsubstituted C3-C10 cycloalkyl, a substituted or unsubstituted 3-10 membered heterocycloalkyl;
B is selected from the group consisting of: a substituted or unsubstituted C6-C10 aryl, a substituted or unsubstituted 5-10 membered heteroaryl;
C is selected from the group consisting of: H. OH, -N (Ra) Rb, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-10 membered heteroaryl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl;
Unless otherwise specified, the term "substituted" refers to a radical in which a hydrogen atom is replaced with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen, deuterated, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C1-C6 alkyl S (=o) 2 -, oxo (=o), -CN, -OH, -N (Ra) Rb, carboxyl, or a substituted or unsubstituted group selected from the group consisting of: C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 amino, C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-12 membered heterocyclyl having 1-3 heteroatoms selected from N, S and O, - (CH 2) -C6-C10 aryl, - (CH 2) - (5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O), and said substituents are selected from the group consisting of: halogen, C1-C6 alkyl, C1-C6 alkynyl, C1-C6 alkoxy, oxo, -CN, -NH 2, -OH, C6-C10 aryl, C1-C6 amino, C2-C6 amido, 5-to 10-membered heteroaryl having 1-3 heteroatoms selected from N, S and O;
Wherein Ra and Rb are each independently selected from the group consisting of: H. a substituted or unsubstituted C1-C4 alkyl group; or Ra, rb, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted 3-to 10-membered heterocycloalkyl having at least 1 (e.g., 1, 2, 3) N heteroatoms and 0-2 heteroatoms selected from O, S.
In another preferred embodiment, for R 3, the substitution means having one or more substituents selected from group A: halogen, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, -OH, -N (Ra) Rb.
In another preferred embodiment, R 1、R2 together form a substituted or unsubstituted- (CH 2)n2 -structure) wherein n 2 is 1, 2 or 3.
In a further preferred embodiment of the present invention,At positions 2, 3 or 4.
In another preferred embodiment, the compound of formula I has the structure shown in I-a:
in a further preferred embodiment of the present invention, For/>
In another preferred embodiment, any of R 1、R2、R3、R4、n1、L1、L2、L3, A, B and C in the compounds described are each a group corresponding to a particular compound described in Table 1.
In another preferred embodiment, the compound of formula I is selected from the following table:
In a second aspect of the present invention, there is provided a pharmaceutical composition comprising;
(a) A therapeutically effective amount of a compound of formula I according to the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof; and (b) a pharmaceutically acceptable carrier.
In another preferred embodiment, the pharmaceutical composition further comprises one or more anti-cancer agents and/or immunosuppressives, preferably selected from the group consisting of: PARP1/2 inhibitors, chemotherapeutics inducing DNA damage to cancer cells, DNA alkylating chemotherapeutics, DNA or RNA synthesis inhibitors, EGFR, ALK or FGFR tyrosine receptor kinase inhibitors, KRAS, MEK or ERK tumor signaling pathway inhibitors, tumor immunotherapeutic drugs (e.g. PD-1 antibodies, PD-L 1 antibodies, etc.).
In another preferred embodiment, the pharmaceutical composition further comprises one or more anti-cancer agents and/or immunosuppressives, preferably selected from the group consisting of: oxipa, lu Kapa, nilapamide, methotrexate, capecitabine, gemcitabine, doxifluridine, pemetrexed disodium, pazopanib, imatinib, erlotinib, lapatinib, gefitinib, vandetanib, herceptin, bevacizumab, rituximab, trastuzumab, paclitaxel, vinorelbine, docetaxel, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, bleomycin, letrozole, tamoxifen, fulvestrant, trazosin, fluzamide, leuprolide, amoxazole, cyclophosphamide, carmustine, nimustine, semustine, nitrogen, marflange, flufluvaldeconing, carboplatin, cisplatin, topotecan, camptothecine, topotecan, evericin, sequoyitol, 6-daptomycin, amitraz, 6-mercaptomycin, thiomycin, amitraz, and other drugs.
In a third aspect the present invention provides the use of a compound of formula I as described in the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as described in the second aspect of the invention, for the manufacture of a pharmaceutical composition for the treatment and/or prophylaxis of a disease or condition associated with CDK12 and/or CDK13 activity or expression.
In another preferred embodiment, the disease or disorder is cancer.
In another preferred embodiment, the cancer is selected from the group consisting of: t-cell acute lymphoblastic leukemia (T-ALL), small Cell Lung Cancer (SCLC), neuroblastoma, non-small cell lung cancer (NSCLC), colon cancer, acute Myelogenous Leukemia (AML), chronic Lymphocytic Leukemia (CLL), non-hodgkin's lymphoma (NHL), multiple myeloma, ovarian cancer, ewing's sarcoma, skin cancer, prostate cancer, liver cancer, pancreatic cancer, gastric cancer, esophageal cancer, bladder cancer, brain tumor, squamous cell carcinoma, peritoneal cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, carcinoma in situ, lymphoma, neurofibromatosis, thyroid cancer, bone cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma, or sarcoma.
In another preferred embodiment, the cancer is a kinase highly expressed cancer selected from the group consisting of: CDK12, CDK13, KRAS, or a combination thereof.
In another preferred embodiment, the cancer is non-CDK 7 high expression.
In a fourth aspect of the present invention, there is provided a process for the preparation of a compound of formula I according to the first aspect of the present invention, comprising the steps of:
(a) Reacting the compounds of formula A4 and formula A5 in an inert solvent to form a compound of formula I:
In the method, in the process of the invention,
Z is selected from: halogen, -OMs, -OTs, -OTf, -OAc or-OAr;
X1、X2、R1、R2、R3、R4、L1、L2、L3、A、B、C、 And n1 is as defined in the first aspect of the invention.
In a fifth aspect of the present invention, there is provided a process for the preparation of a compound of formula I comprising the steps of:
(b) Reacting the compounds of formula A6 and formula A7 in an inert solvent to form a compound of formula I:
In the method, in the process of the invention,
X1、X2、R1、R2、R3、R4、L1、L2、L3、A、B、C、 And n 1 are as defined in the first aspect of the invention.
In a sixth aspect of the invention, there is provided an intermediate compound having a structure selected from: a1, A2, A3 or A4 has the structural formula:
Wherein Z is selected from: H. halogen, -OMs, -OTs, -OTf, -OAc or-OAr;
X1、X2、R1、R2、R3、R4、L1、L2、L3、A、B、C、 And n1 is as defined in the first aspect of the invention.
In a seventh aspect of the invention there is provided the use of a compound A1, A2, A3 or A4 for the preparation of compound I.
In an eighth aspect of the invention there is provided an inhibitor of CDK12 and/or CDK13 comprising:
A compound of formula I according to the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to the second aspect of the invention.
In a ninth aspect of the invention, there is provided a method of selectively inhibiting a cell cycle dependent kinase in vitro comprising the steps of:
contacting a cell cycle dependent kinase with a compound of formula I, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as described in the first aspect of the invention, or a pharmaceutical composition according to the second aspect of the invention, thereby selectively inhibiting the cell cycle dependent kinase.
In another preferred embodiment, the method is non-therapeutic and non-diagnostic.
In another preferred embodiment, the cell cycle dependent kinase CDK is selected from the group consisting of: CDK12, CDK13, or a combination thereof, preferably CDK12 and CDK13.
In another preferred embodiment, said "selectively inhibiting" means that the ratio (E1/E2) of the inhibitory activity E1 of said compound against a targeted CDK (e.g. CDK12 and/or CDK 13) to the inhibitory activity E2 against a non-targeted kinase (e.g. CDK7 or other non-targeted kinase selected from Table 4) is ≡2, preferably ≡5, more preferably ≡10.
In another preferred embodiment, the inhibitory activity E is the reciprocal of EC 50.
In a tenth aspect of the present invention, there is provided a method of inhibiting the growth or proliferation of tumour cells in vitro comprising the steps of,
Contacting a tumor cell with a compound of formula I as described in the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as described in the second aspect of the invention.
In another preferred embodiment, the method is non-therapeutic and non-diagnostic.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.
Drawings
FIG. 1 shows the effect of representative compounds on Ser2 and Ser5 site phosphorylation of Pol II in H3122 (A) or A549 (B) cells.
FIG. 2 shows the competitive effect of representative compounds such as ZSQ-38, ZSQ8-36, etc. on covalent binding of THZ1-biotin to CDK7 or 12 in H3122 cells at a concentration of 1. Mu.M.
FIG. 3 shows the effect of representative compounds such as ZSQ-36 and ZSQ-66 on CDK7 or 12 catalytic Pol II CTD Ser5 site phosphorylation modification at various concentrations.
Fig. 4 shows concentration time curves of representative compounds ZSQ-38 and ZSQ8-36 in plasma, as well as pharmacokinetic parameters.
FIG. 5 shows the inhibitory effect of representative compounds ZSQ-38 and ZSQ-36 on growth proliferation of various cell lines at a concentration of 1. Mu.M.
Detailed Description
The present inventors have conducted extensive and intensive studies and, through extensive screening and testing, unexpectedly developed a class of compounds having high inhibitory activity against CDK12/13, but no or low inhibitory activity against CDK 7. The compounds of the invention are organic arsine-based cell cycle dependent kinase inhibitors of formula I, and in the structure of the compounds of the invention, the organic arsine group (moeity) is the moiety that covalently interacts with the active site of CDK12/13, thus providing excellent inhibitory activity and better specificity. Experimental results show that the compound has unexpected excellent specificity of targeting CDK12/13, and is high in safety and less in toxic and side effects. In addition, the compound of the invention has excellent pharmacokinetic property and long half life, and is suitable for patent medicine. The present invention has been completed on the basis of this finding.
Terminology
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Terminology
Unless otherwise stated, the term "alkyl" by itself or as part of another substituent refers to a straight or branched hydrocarbon radical having the indicated number of carbon atoms (i.e., C1-8 represents 1-8 carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
Unless otherwise stated, the term "alkenyl" refers to an unsaturated alkyl group having one or more double bonds. Similarly, the term "alkynyl" refers to an unsaturated alkyl group having one or more triple bonds. Examples of such unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2- (butadienyl), 2, 4-pentadienyl, 3- (1, 4-pentadienyl), ethynyl, 1-and 3-propynyl, 3-butynyl and higher homologs and isomers.
Unless otherwise stated, the term "cycloalkyl" refers to a hydrocarbon ring having the specified number of ring atoms (e.g., C 3-10 cycloalkyl) and either fully saturated or having no more than one double bond between ring vertices. "cycloalkyl" also refers to bicyclic and polycyclic hydrocarbon rings, such as bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, and the like.
Unless otherwise indicated, the term "heterocycloalkyl" refers to cycloalkyl groups containing one to five heteroatoms selected from N, O and S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom is optionally quaternized. Heterocycloalkyl groups may be monocyclic, bicyclic or polycyclic ring systems. Non-limiting examples of heterocycloalkyl groups include pyrrolidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidone, hydantoin, dioxolane, phthalimide, piperidine, 1, 4-dioxane, morpholine, thiomorpholine-S-oxide, thiomorpholine-S, S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, and the like. Heterocycloalkyl groups can be attached to the remainder of the molecule via a ring carbon or heteroatom. Terms such as cycloalkylalkyl and heterocyclylalkyl refer to a cycloalkyl or heterocycloalkyl group attached to the remainder of the molecule through an alkyl or alkylene linker. For example, cyclobutylmethyl-is a cyclobutyl ring attached to the methylene linker of the rest of the molecule.
Unless otherwise stated, the term "alkylene" by itself or as part of another substituent refers to a divalent group derived from an alkane, such as-CH 2CH2CH2CH2 -. Alkyl (or alkylene) groups typically have 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms (e.g., 1, 2, 3, 4, 5, or 6) being preferred in the present invention. "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, typically having 4 or fewer carbon atoms. Similarly, "alkenylene" or "alkynylene" refer to an unsaturated form of "alkylene" having a double or triple bond, respectively.
Unless otherwise stated, the terms "alkoxy" or "alkyloxy", "alkylamino", "or" alkylamino "and" alkylthio "or" alkylthio "(or thioalkoxy) are used in their conventional sense to refer to those alkyl groups attached to the rest of the molecule via an oxygen atom, amino group, or sulfur atom, respectively. In addition, for dialkylamino groups, the alkyl moieties can be the same or different and can be combined with the nitrogen atom to which each alkyl group is attached to form a 3-7 membered ring.
Unless otherwise stated, the term "halo" or "halogen" by itself or as part of another substituent refers to a fluorine, chlorine, bromine, or iodine atom. Furthermore, terms such as "haloalkyl" are meant to include monohaloalkyl or polyhaloalkyl. For example, the term "C 1-4 haloalkyl" is meant to include trifluoromethyl, 2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
Unless otherwise stated, the term "aryl" refers to a polyunsaturated (usually aromatic) hydrocarbon group, which may be a single ring or multiple rings (up to three rings) fused together or covalently linked. The term "heteroaryl" refers to an aryl group (or ring) containing 1 to 5 heteroatoms selected from N, O, and S, which may be monocyclic or multiple rings (bicyclic, up to tricyclic) fused together or covalently linked wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atoms are optionally quaternized. Heteroaryl groups may be attached to the remainder of the molecule through heteroatoms. Non-limiting examples of aryl groups include phenyl, naphthyl, and biphenyl, while non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl (benzotriazin yl), purinyl, benzimidazolyl, benzopyrazolyl, benzotriazole, benzisoxazolyl, isobenzofuranyl (isobenzofur yl), isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridine, benzothiazolyl, benzofuranyl, benzothienyl, indolyl, quinolinyl, isoquinolinyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furanyl, thienyl, and the like. The substituents for each of the above aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
As used herein, the term "heteroatom" is intended to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
For the compounds provided herein, a bond from a substituent (typically an R group) to the center of an aromatic ring (e.g., benzene, pyridine, etc.) will be understood to refer to a bond that provides a connection at any available vertex of the aromatic ring. In some embodiments, the description also includes linkages on rings fused to aromatic rings. For example, a bond drawn to the center of the indole benzene moiety will represent a bond to any available vertex of the six-or five-membered ring portion of the indole.
Unless otherwise indicated, all compounds present in the present invention are intended to include all possible optical isomers, such as single chiral compounds, or mixtures of various chiral compounds (i.e., racemates). Among all the compounds of the invention, each chiral carbon atom may optionally be in the R configuration or in the S configuration, or in a mixture of R and S configurations.
Certain compounds of the invention possess an asymmetric carbon atom (optical center) or double bond; racemates, diastereomers, geometric isomers, regioisomers and individual isomers (e.g., isolated enantiomers) are all intended to be included within the scope of the present invention. When compounds provided herein have a defined stereochemistry (denoted R or S, or indicated with dashed or wedge-shaped bonds), those compounds will be understood by those skilled in the art to be substantially free of other isomers (e.g., at least 80%,90%,95%,98%,99% and up to 100% free of other isomers).
In this context, the term "substituted" means that one or more hydrogen atoms on the group are replaced by substituents selected from the group consisting of: halogen, deuterated, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C1-C6 alkyl S (=O) 2 -, oxo (=O), -CN, -OH, -N (R a)Rb, carboxy, or a substituted or unsubstituted group selected from the group consisting of C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 amino, C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, - (CH 2) -C6-C10 aryl, - (CH 2) - (5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O), and said substituent is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, -CN, -C6 alkoxy, C6-C6 alkenyl, 5-C6 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O, - (CH 2) -C6-C10 aryl, - (CH 2) - (5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O.
As used herein, the terms "comprising," "including," or "comprising" mean that the various ingredients can be used together in a mixture or composition of the invention. Thus, the terms "consisting essentially of and" consisting of are encompassed by the term "containing.
As used herein, the term "pharmaceutically acceptable" ingredient refers to a substance that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response), commensurate with a reasonable benefit/risk ratio.
As used herein, the term "therapeutically effective dose" refers to any amount of a drug that, when used alone or in combination with another therapeutic agent, promotes disease regression as evidenced by a decrease in the severity of disease symptoms, an increase in the frequency and duration of disease-free symptoms, or prevention of a disorder or disability caused by the disease. "therapeutically effective dose" of a drug of the present invention also includes a "prophylactically effective dose," which is any amount of a drug that, when administered alone or in combination with another therapeutic agent, inhibits the occurrence or recurrence of a disease in a subject at risk of developing or suffering from recurrence of the disease.
As used herein, "pharmaceutically acceptable salts" refers to salts of the compounds of the invention with acids or bases that are suitable for use as medicaments. Pharmaceutically acceptable salts include inorganic and organic salts. One preferred class of salts is the salts of the compounds of the present invention with acids. Suitable salts forming acids include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenesulfonic acid, and the like; acidic amino acids such as aspartic acid and glutamic acid. One preferred class of salts is the salts of the compounds of the present invention with bases. Suitable bases for salt formation include, but are not limited to: inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate and sodium phosphate, and organic bases such as ammonia water, triethylamine, diethylamine and piperazine.
Some of the compounds of the present invention may be crystallized or recrystallized from water or various organic solvents, in which case various solvates may be formed. Solvates of the present invention include stoichiometric solvates such as hydrates and the like, as well as compounds containing variable amounts of water formed when prepared by the low pressure sublimation drying process.
The invention also includes all suitable isotopic variations of the compounds of the present invention. Isotopic variations of compounds of the present invention are defined as those in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2H、3H、11C、13C、14C、15N、17O、18O、35S、18F and 36 Cl, respectively. Some isotopic variants of the present invention, for example, those into which a radioisotope (e.g., 3 H or 14 C) is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred because they are easy to prepare and detect. Furthermore, substitution with isotopes (e.g., deuterium, i.e., 2 H) may afford certain therapeutic advantages resulting from increased metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and therefore may be preferred in some circumstances. Isotopic variations of the compounds of the present invention can generally be prepared by conventional procedures, for example, by exemplary methods or by using suitable reagents for the appropriate isotopic variations described in the experimental section below.
Indicating a connection to other atoms.
As used herein, "treating" refers to alleviating, slowing progression, attenuating, preventing, or maintaining an existing disease or disorder (e.g., cancer). Treatment also includes curing, preventing the development of, or alleviating to some extent, one or more symptoms of the disease or disorder.
As used herein, "patient" refers to an animal, preferably a mammal, more preferably a human. The term "mammal" refers to a warm-blooded vertebrate mammal, including, for example, cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice, pigs, and humans.
As used herein, "ZSQ-5-38" is used interchangeably with "ZSQ5-38", "ZSQ538" to denote ZSQ-5-38 compounds, with similar numbering usage rules being the same.
Active ingredient
As used herein, "a compound of the invention" refers to a compound of formula I, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof;
X1、X2、R1、R2、R3、R4、L1、L2、L3、A、B、C、 And n1 is as defined in the first aspect of the invention.
Preparation method
The present invention provides methods for preparing compounds of formula I, where the compounds of the present invention may be prepared by a variety of synthetic procedures, and exemplary methods for preparing these compounds may include, but are not limited to, the schemes described below.
Preferably, the compounds of formula I of the present invention can be accomplished by the exemplary methods described in the schemes and examples below, as well as by related published literature procedures used by those skilled in the art.
During specific operations, steps in the method may be expanded or combined as desired.
Step i: as the protective agent, ethylene dithiol, ethylene glycol, etc. can be used by protecting the arsenite functional group of A1 with an ester or amide.
Step ii: r 3 substituent is introduced into the amino group of A2 through S N substitution reaction, and R3-halogen can be used for reaction under alkaline conditions (such as sodium hydride).
Step iii: the acylation reaction of the benzenoid group at A3 introduces the L1 group, which can be catalyzed by (but is not limited to) phosphorus oxychloride reagent.
Step iv: the a functional site of A5 is linked to L 1 of A4 by an acylation reaction, a urea formation reaction or S N substitution.
The reactions in each of the above steps are conventional reactions known to those skilled in the art. Reagents and starting compounds used in the synthetic routes are commercially available or can be prepared by one skilled in the art with reference to known methods depending on the different compound structures designed, unless otherwise specified.
Pharmaceutical compositions and methods of administration
Because the compounds of the present invention have excellent inhibitory activity against cell Cycle Dependent Kinase (CDK), the compounds of the present invention, and pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions containing the compounds of the present invention as a main active ingredient are useful for treating, preventing and alleviating diseases or disorders associated with CDK activity or expression level.
Preferably, the compounds of the present invention are useful for the treatment of cancer. Representative cancers include (but are not limited to): t-cell acute lymphoblastic leukemia (T-ALL), small Cell Lung Cancer (SCLC), neuroblastoma, non-small cell lung cancer (NSCLC), colon cancer, acute Myelogenous Leukemia (AML), chronic Lymphocytic Leukemia (CLL), non-hodgkin's lymphoma (NHL), multiple myeloma, ovarian cancer, ewing's sarcoma, skin cancer, prostate cancer, liver cancer, pancreatic cancer, gastric cancer, esophageal cancer, bladder cancer, brain tumor, squamous cell carcinoma, peritoneal cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, carcinoma in situ, lymphoma, neurofibromatosis, thyroid cancer, bone cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma, or sarcoma.
The pharmaceutical compositions of the present invention comprise a safe and effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical compositions contain 1-2000mg of the compound of the invention per dose, more preferably 10-500mg of the compound of the invention per dose. Preferably, the "one dose" is a capsule or tablet.
"Pharmaceutically acceptable carrier" means: one or more compatible solid or liquid filler or gel materials which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. "compatible" as used herein means that the components of the composition are capable of blending with and between the compounds of the present invention without significantly reducing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, and the like), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, and the like), polyols (e.g., propylene glycol, glycerol, mannitol, sorbitol, and the like), emulsifiers (e.g.) Wetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizing agents, antioxidants, preservatives, pyrogen-free water and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, e.g., glycerin; (d) Disintegrants, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent, such as paraffin; (f) an absorption accelerator, e.g., a quaternary amine compound; (g) Wetting agents, such as cetyl alcohol and glycerol monostearate; (h) an adsorbent, for example, kaolin; and (i) a lubricant, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be released in a delayed manner in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. The active compound may also be in the form of microcapsules with one or more of the above excipients, if desired.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances and the like.
In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar-agar or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if necessary.
The compounds of the invention may be administered alone or in combination with other pharmaceutically acceptable compounds. Such as anti-cancer agents, (e.g., PARP1/2 inhibitors (olapanib (Olaparid), lu Kapa b, or nippanib (Niraparib), etc.), chemotherapeutics inducing DNA damage to cancer cells (cisplatin, carboplatin, or oxaliplatin, etc.), DNA alkylating chemotherapeutics (nimustine, etc.), inhibitors of DNA or RNA synthesis (gemcitabine, etc.), tyrosine receptor kinase inhibitors such as EGFR, ALK, or FGFR, tumor signaling pathway inhibitors such as KRAS, MEK, or ERK, tumor immunotherapeutic agents (PD-1 antibodies, PD-L 1 antibodies, etc.), in certain embodiments, the compounds of the invention are administered in combination with other conventional cancer therapies, e.g., radiation therapy or surgery.
In certain embodiments, the CDK inhibitor of the invention is used in the same or separate formulations either concurrently with, or sequentially with, other agents that are part of a combination therapeutic regimen.
The general range of therapeutically effective doses for a compound of formula I or a composition of a compound of formula I will be: about 1 to 2000 mg/day, about 10 to about 1000 mg/day, about 10 to about 500 mg/day, about 10 to about 250 mg/day, about 10 to about 100 mg/day, or about 10 to about 50 mg/day. A therapeutically effective dose will be administered in one or more doses. However, it will be appreciated that the particular dosage of a compound of the invention for any particular patient will depend on a variety of factors, such as the age, sex, weight, general health, diet, individual response of the patient to be treated, the time of administration, the severity of the disease to be treated, the activity of the particular compound administered, the dosage form, the mode of application and concomitant medication. The therapeutically effective amount for a given situation can be determined by routine experimentation and is within the ability and judgment of a clinician or physician. In any event, the compound or composition will be administered in multiple doses based on the individual condition of the patient and in a manner that allows for the delivery of a therapeutically effective amount.
The main advantages of the invention include:
1. the compound of the present invention has an organic arsine group (moeity) as a moiety which is covalently reacted with the active site of CDK12/13 for the first time, thus providing excellent inhibitory activity and better specificity.
2. The inhibiting activity of CDK12, 13 is superior to the existing inhibitor, and can effectively inhibit the growth and proliferation of cancer cells.
3. The inhibitor has no obvious inhibition to other kinases in cells, high selectivity, good targeting property, good safety and no obvious toxic or side effect under the effective concentration;
4. has ideal pharmacokinetic properties: the half-life is long and the area under the drug concentration-time curve (AUC) is high.
5. The combination of the compound and CDK12 and 13 is irreversible combination, the efficacy duration is longer, and the curative effect is longer.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental methods, in which specific conditions are not noted in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
Example 1
Synthetic route to Compounds ZSQ-38
Synthesis of Compound (4-aminophenyl) arsinic acid (ZSQ-1-18)
4-Aminophenylarsonic acid (108.5 g,500 mmol) was dissolved in 300ml ethanol and the mixed solution was heated to reflux. Phenylhydrazine (92 ml,1 mol) was added dropwise (over 1 h) with a large amount of nitrogen generated during the addition, and when the nitrogen generation was slowed down, stirring under reflux was continued for 1.5h. The mixture was concentrated by distillation under reduced pressure, and sodium hydroxide solution (40 g in 400ml of water) was added thereto, followed by 400ml of diethyl ether. The solution was separated, a saturated ammonium chloride solution (400 ml) was added to the aqueous phase, and the mixture was stirred at 0℃for 1 hour, whereby a large amount of white solid was precipitated. Filtration gave a white needle-like solid which was dried in vacuo to give 40g of product in 40% yield.
Synthesis of Compound 4- (1, 3, 2-dithioarsin-2-yl) aniline (ZSQ-1-23)
ZSQ-1-18 (40 g, 199mmol) was dissolved in 200ml absolute ethanol and heated to reflux. Then, ethanedithiol (20 ml,240 mmol) was added dropwise to the mixed solution over 30min, and heating and stirring were continued for 30min. Subsequently, the mixture was cooled in ice water and filtered to give a crude product, which was recrystallized from ethanol to give 42g of white solid in 81% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin pent-2-yl) phenyl) -2-bromoacetamide (ZSQ-5-4)
ZSQ-1-23 (1.03 g,4 mmol) and triethylamine (0.83 ml,6 mmol) were dissolved in 20ml of dry DCM and stirred at 0deg.C. Bromoacetyl bromide (0.38 ml,4.4 mmol) was added dropwise over 15min and stirring was continued for 1h at 0 ℃. The mixture was diluted with DCM (20 ml), washed with 2M dilute hydrochloric acid solution (30 ml), water (50 ml), saturated sodium bicarbonate solution (30 ml), saturated sodium chloride solution (30 ml) in this order, extracted with DCM, the organic phases combined, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica eluting with PE/EA (4:1) afforded 1.02g of a yellow solid in 67% yield.
Synthesis of Compound 3- (2, 5-dichloropyrimidin-4-yl) -1H-indole (ZSQ-3-76)
Methyl magnesium bromide (1M in tetrahydrofuran, 100ml,100 mmol) was added dropwise to a solution of indole (11.7 g,100 mmol) in THF (60 ml) at 0deg.C over 30min. The solution was stirred for a further 30min at 0 ℃.2, 4, 5-trichloropyrimidine (5.73 ml,50 mmol) was added dropwise to give a yellow solution. The ice bath was removed and the solution was stirred at room temperature for 1h to give a red solution. The mixed solution was warmed to 60 ℃ and stirred for an additional 1.5h. The mixture was cooled to room temperature, acetic acid (100 ml) was added dropwise, water (100 ml) and THF (20 ml) were added, and the mixture was stirred at 60 ℃ for 20min to give a two-phase solution. Layering and adding petroleum ether (100 ml) to the organic solution resulted in crystallization of the solid. The solid was collected by filtration, washed with petroleum ether (20 ml) and dried under vacuum to give 7.02g of a yellow solid in 53% yield.
Synthesis of Compound 3- (2, 5-dichloropyrimidin-4-yl) -1- (phenylsulfonyl) -1H-indole (ZSQ-5-26)
ZSQ-3-76 (5.28 g,20 mmol), naOH (1.2 g,30 mmol) and Bu 4NHSO4 (5.8 g,10 mmol) were dissolved in 100ml of dichloromethane and benzenesulfonyl chloride (3.84 ml,30 mmol) was added dropwise at room temperature. The reaction mixture was stirred at room temperature for 3h. The mixture was quenched with water (100 ml) and extracted with DCM (50 ml. Times.3). The combined organic layers were dried over anhydrous Na 2SO4, filtered, concentrated and purified by column chromatography on silica gel eluting with DCM/EA (8:1) to give 6.79g of a white solid in 84% yield.
Synthesis of tert-butyl Compound (R) -3- ((5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate (ZSQ-8-30)
ZSQ-5-26 (316 mg,1.5 mmol), (R) -1-Boc-3-aminopiperidine (300 mg,1.5 mmol) and DIPEA (0.74 ml,4.5 mmol) were mixed and dissolved in 3ml N-methylpyrrolidone. The mixed solution was heated at 135℃and stirred for 3h. The cooled solution was directly purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:9) to give 802mg of a yellowish brown powder in 94% yield.
Synthesis of the Compound (R) -5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) -N- (piperidin-3-yl) pyrimidin-2-amine (ZSQ-8-31)
ZSQ-8-30 (803 mg,1.4 mmol) and 1ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:6), to give 620mg of a yellowish brown powder in 94% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamide (ZSQ-8-34)
ZSQ-8-31 (140 mg,0.3 mmol), DIPEA (0.15 ml,0.9 mmol) and ZSQ-5-4 (114 mg,0.3 mmol) were dissolved in 5ml THF at room temperature and the mixed solution stirred at room temperature for 4h. Then washed with 2N dilute hydrochloric acid solution (20 ml) and extracted with EA (3X 30 ml), followed by washing with water (2X 20 ml). The combined organic phases were dried over anhydrous Na 2SO4, filtered and concentrated under reduced pressure, separated and purified by column chromatography on silica gel eluting with DCM/EA (4:1) to give 209mg of a white powder in 9 1% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamide (ZSQ-8-36)
ZSQ-8-34 (209 mg,0.27 mmol) of anhydrous potassium carbonate (113 mg,0.82 mmol) was dissolved in a mixed solution of 5ml of anhydrous methanol and 5ml of anhydrous THF, and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, pH was adjusted to weak acidity with TFA, and the reaction mixture was directly purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:6), to give 123mg of a yellow powder in 73% yield.
Synthesis of Compound (R) - (4- (2- (3- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamido) phenyl) arsinic acid (ZSQ-5-38)
ZSQ-8-36 (123 mg,0.19 mmol), mercuric perchlorate trihydrate (71 mg,0.157 mmol) was dissolved in 3ml DMSO, the mixed solution was stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:4) to give 102mg of yellow powder in 92% yield.
Example 2:
Synthetic route to Compounds ZSQ-70
Synthesis of tert-butyl (ZSQ-5-57-1) carbamate, the compound (3- (2- ((4- (1, 3, 2-dithioarsin-2-yl) phenyl) amino) -2-oxoethyl) -phenyl)
ZSQ-1-23 (272 mg,1.05 mmol), 3-t-butoxycarbonylaminophenylacetic acid (251 mg,1 mmol), HATU (560 mg,1.5 mmol) and DIPEA (496 ul,3 mmol) were dissolved in 5ml DCM and left to stir at room temperature for 4h. After the reaction was completed, it was washed with H 2 O (20 ml. Times.2), saturated NaCl solution (20 ml), extracted with 20ml DCM, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography on silica gel eluting with PE/EA (3:1) to give 412mg of a white solid in 83% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3-aminophenyl) acetamide (ZSQ-5-57-2)
ZSQ-5-57-1 (412 mg,0.83 mmol) and 1ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:7), to give 290mg of a white solid in 89% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acetamide (ZSQ-5-63)
ZSQ-5-26 (202 mg,0.5 mmol), ZSQ-5-57-2 (196 mg,0.5 mmol) and p-toluenesulfonic acid monohydrate (284 mg,1.5 mmol) were mixed and dissolved in 2ml of N-methylpyrrolidone. The mixed solution was heated at 135℃and stirred for 2h. The cooled solution was directly purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:9) to give 86mg of a yellow powder in 22% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-chloro-4- (1H-indol-3-yl) -pyrimidin-2-yl) amino) phenyl) acetamide (ZSQ-5-66)
ZSQ-5-63 (86 mg,0.11 mmol) in a mixed solution of anhydrous potassium carbonate (47 mg,0.33 mmol) in 3ml of anhydrous methanol and 3ml of anhydrous THF was stirred at room temperature for 4 hours. After the reaction was completed, pH was adjusted to weak acidity with TFA, and the reaction mixture was directly purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:6), to give 31mg of a yellow powder in 45% yield.
Synthesis of Compound (4- (2- (3- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acetamido) -phenyl) arsinic acid (ZSQ-5-70)
ZSQ-5-66 (31 mg,0.05 mmol), mercuric perchlorate trihydrate (18 mg,0.04 mmol) was dissolved in 2ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:4) to give 21mg of yellow powder in 75% yield.
Example 3
Synthetic route to Compounds ZSQ-7-84
Synthesis of tert-butyl (ZSQ-7-72) piperidine-1-carboxylate (3- (((5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) methyl) compound
ZSQ-5-26 (316 mg,1.5 mmol), 1-Boc-3-aminomethylpiperidine (354 mg,1.65 mmol) and DIPEA (0.74 ml,4.5 mmol) were mixed and dissolved in 3ml N-methylpyrrolidone. The mixed solution was heated at 135℃and stirred for 3h. The cooled solution was directly purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:9) to give 630mg of a yellow solid in 72% yield.
Synthesis of the Compound 5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) -N- (piperidin-3-ylmethyl) -pyrimidin-2-amine (ZSQ-7-76)
ZSQ-7-72 (630 mg,1.08 mmol) and 1ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:6), to give 501mg of a tan solid in 96% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -3- (((5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) methyl) piperidine-1-carboxamide (ZSQ-7-80)
ZSQ-1-23 (130 mg,0.5 mmol) of bis (trichloromethyl) carbonate (59 mg,0.2 mmol) was dissolved in 5ml THF and stirred at 0deg.C, DIPEA (207 ul,1.25 mmol) was added dropwise and the mixed solution after addition was stirred at 0deg.C for 1h. ZSQ-7-76 (241 mg,0.5 mmol) was added, and after addition was completed stirring was continued at 0deg.C for 0.5h, and then was allowed to stir at room temperature for 2h. After completion of the reaction, washed successively with 2N dilute hydrochloric acid solution (20 ml), saturated sodium bicarbonate solution (20 ml), saturated sodium chloride solution (20 ml), extracted with 40ml DCM, the combined organic phases dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica eluting with PE/EA (2:1) gave 178mg of a white powder in 46% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -3- (((5-chloro-4- (1H-indol-3-yl) -pyrimidin-2-yl) amino) methyl) piperidine-1-carboxamide (ZSQ-7-83)
ZSQ-7-80 (178 mg,0.23 mmol) of anhydrous potassium carbonate (96 mg,0.69 mmol) was dissolved in a mixed solution of 5ml of anhydrous methanol and 5ml of anhydrous THF, and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, pH was adjusted to weak acidity with TFA, and the reaction mixture was directly purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:7), to give 124mg of a yellow powder in 86% yield.
Synthesis of Compound (4- (3- (((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) methyl) piperidine-1-carboxamido) phenyl) arsinic acid (ZSQ-7-84)
ZSQ-7-83 (124 mg,0.2 mmol), mercuric perchlorate trihydrate (71 mg,0.16 mmol) was dissolved in 3ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:4) to give 78mg of yellow powder in 70% yield.
Example 4
Synthetic route to Compound ZSQ-7-105
Synthesis of Compound 2-formyl-3-methylbutanenitrile (ZSQ-7-74)
2M lithium diisopropylamide solution (27.5 ml,55 mmol) was mixed in 50ml of dry THF, stirred at-78℃and isovaleronitrile (5.24 ml,50 mmol) was added dropwise, stirring was continued for 30min after addition was completed, ethyl formate (4.85 ml,60 mmol) was mixed in 25ml of dry THF, added dropwise to the mixed solution (over 30 min) at-78℃and stirring was continued for 45min, and then the mixture was allowed to move to room temperature and stirred for 14h. After completion of the reaction, 10ml of H 2 O was added to quench, the mixed solution was concentrated, diluted hydrochloric acid solution was added to adjust pH to 3, then extracted with EA (20 ml. Times.3), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and dried by suction to give 5g of a tan oily crude product.
Synthesis of Compound 4-isopropyl-1H-pyrazol-3-amine (ZSQ-7-81)
ZSQ-7-74 (5 g,45 mmol), hydrazine hydrate (3.27 ml,67.5 mmol) and acetic acid (5 ml,89 mmol) were mixed in 75ml absolute ethanol, heated in a sealed tube and stirred for 16h. After completion of the reaction, the mixture was concentrated to leave 1/3, washed with saturated sodium bicarbonate solution (40 ml) (pH was adjusted to alkaline), extracted with DCM (30 ml. Times.2), and washed with saturated sodium chloride solution (40 ml). The combined organic phases were dried over anhydrous sodium sulfate, and the filtrate was concentrated to dryness without further purification to give 6.7g of a yellow solid.
Synthesis of the Compound 3-isopropylpyrazolo [1,5-a ] pyrimidine-5, 7-diol (ZSQ-7-85)
ZSQ-7-81 (1.25 g,10 mmol) was dissolved in a lock tube containing 30ml of dry ethanol, 20% sodium ethoxide solution (3.74 g,11 mmol) was added, the mixed solution was heated to reflux temperature and stirred for 22h. After the completion of the reaction, the reaction mixture was concentrated, diluted with water (20 ml), adjusted to pH 3 with a dilute hydrochloric acid solution, and a large amount of solids were precipitated, filtered and washed with water several times. A yellow powder was obtained, which after drying gave 1.29g of a white powder with a yield of 66%.
Synthesis of the Compound 5, 7-di-chloro-3-isopropylpyrazolo [1,5-a ] pyrimidine (ZSQ-7-88)
ZSQ-7-85 (1.29 g,6.67 mmol) and N, N-dimethylaniline (84 ul,0.67 mmol) were mixed in a sealed tube containing 15ml of phosphorus oxychloride, heated to 115℃overnight and stirred under reflux. After completion of the reaction, the mixed solution was concentrated, the remaining solution was dropwise added to ice water, extracted with DCM a plurality of times, washed with saturated sodium chloride solution (30 ml), and the organic phases were combined. Drying over anhydrous sodium sulfate, filtering, concentrating and purifying by silica gel column chromatography eluting with PE/EA (4:1) to give 950mg of yellow solid in 62% yield.
Synthesis of the Compound N-benzyl-5-chloro-3-isopropylpyrazolo [1,5-a ] pyrimidin-7-amine (ZSQ-7-90)
ZSQ-7-88 (950 mg,4.13 mmol), DIPEA (1.36 ml,8.26 mmol) and benzylamine (0.9 ml,8.26 mmol) were dissolved in 50ml absolute ethanol, heated to 85℃and stirred overnight. After completion of the reaction, the reaction mixture was concentrated, washed with water (30 ml. Times.2), extracted with EA (30 ml), and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography on silica gel eluting with PE/EA (5:1) to give 1.16g of a white solid in 93% yield.
Synthesis of benzyl (5-chloro-3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) -carbamic acid tert-butyl ester (ZSQ-7-94)
ZSQ-7-90 (902 mg,3 mmol), 4-dimethylaminopyridine (37 mg,0.3 mmol) and di-tert-butyl dicarbonate (897 ul,3.9 mmol) were mixed and dissolved in 15ml THF and stirred at room temperature for 12h. After completion of the reaction, the reaction mixture was washed with H 2 O (20 ml. Times.2), extracted with EA (30 ml) and washed with saturated sodium hydrogencarbonate solution (30 ml). The organic phase was dried over anhydrous sodium sulfate, concentrated by filtration and purified by column chromatography on silica gel eluting with PE/EA (8:1) to give 1.20g of pale yellow flaky solid with 99% yield.
Synthesis of tert-butyl Compound 3- (((7- (benzyl (tert-butoxycarbonyl) amino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino) methyl) piperidine-1-carboxylate (ZSQ-7-96)
Compounds ZSQ-7-94 (400 mg,1 mmol), 1-Boc-3-aminomethylpiperidine (236 mg,1.1 mmol), tris (dibenzylideneacetone) dipalladium (46 mg,0.05 mmol), 1 '-binaphthyl-2, 2' -bisdiphenylphosphine (93 mg,0.15 mmol) and sodium t-butoxide (106 mg,1.1 mmol) were mixed in 3ml toluene and heated to 95℃under nitrogen and stirred for 16h. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3), extracted with EA (40 ml) and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (5:1) to give 554mg of yellow-brown powder in 95% yield.
Synthesis of Compound N 7 -benzyl-3-isopropyl-N 5 - (piperidin-3-ylmethyl) pyrazolo [1,5-a ] pyrimidine-5, 7-diamine (ZSQ-7-98)
ZSQ-7-96 (554 mg,0.96 mmol) and 1ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:5), to give 360mg of a white solid in 99% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -3- (((7- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino) methyl) piperidine-1-carboxamide (ZSQ-7-99)
ZSQ-1-23 (130 mg,0.5 mmol) of bis (trichloromethyl) carbonate (59 mg,0.2 mmol) was dissolved in 5ml THF and stirred at 0deg.C, DIPEA (207 ul,1.25 mmol) was added dropwise and the mixed solution after addition was stirred at 0deg.C for 1h. ZSQ-7-98 (189 mg,0.5 mmol) was added and after the addition was completed stirring was continued at0℃for 0.5h and then brought to room temperature for stirring for 2h. After completion of the reaction, washed successively with 2N dilute hydrochloric acid solution (20 ml), saturated sodium bicarbonate solution (20 ml), saturated sodium chloride solution (20 ml), extracted with 40ml DCM, the combined organic phases dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica eluting with DCM/EA (1:1) gave 162mg of a white powder in 49% yield.
Synthesis of Compound (4- (3- (((7- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino) -methyl) piperidine-1-carboxamido) phenyl) arsinic acid (ZSQ-7-105)
ZSQ-7-99 (80 mg,0.12 mmol), mercury perchlorate trihydrate (38 mg,0.08 mmol) was dissolved in 2ml DMSO, the mixed solution was stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 56mg of white powder in 78% yield.
Example 5
Synthetic route to Compound ZSQ-8-12
Synthesis of benzyl Compound 3- (((tert-butoxycarbonyl) amino) methyl) benzoate (ZSQ-7-104)
3- (N-Boc-aminomethyl) benzoic acid (1.0 g,4 mmol) and potassium carbonate (1.10 g,8 mmol) were dissolved in 10ml DMF and after stirring at room temperature for 20min benzyl bromide (522. Mu.l, 4.4 mmol) was added dropwise and stirring at room temperature was continued for 6h after addition. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3) and extracted with EA. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica eluting with PE/EA (3:1) afforded 1.2g of a white solid in 88% yield.
Synthesis of benzyl 3- (aminomethyl) benzoate (ZSQ-8-1)
ZSQ-7-104 (1.2 g,3.5 mmol) and 1ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:6), to give 800mg of a white solid in 95% yield.
Synthesis of benzyl (ZSQ-8-3) benzoate of Compound 3- (((7- (benzyl (tert-butoxycarbonyl) amino) -3-isopropylpyrrolo [1,5-a ] pyrimidin-5-yl) amino) methyl)
Compounds ZSQ-7-94 (200 mg,0.5 mmol), ZSQ-8-1 (133 mg,0.55 mmol), tris (dibenzylideneacetone) dipalladium (23 mg,0.025 mmol), 1 '-binaphthyl-2, 2' -bisdiphenylphosphine (47 mg,0.075 mmol) and sodium t-butoxide (58 mg,0.6 mmol) were mixed in 2ml toluene and heated to 95℃under nitrogen and stirred for 16h. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3), extracted with EA (40 ml) and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (4:1) to give 154mg of a pale yellow powder in 51% yield.
Synthesis of Compound 3- (((7- (benzyl (tert-butoxycarbonyl) amino) -3-isopropylpyrazolo [1,5-a ] -pyrimidin-5-yl) amino) methyl) benzoic acid (ZSQ-8-6)
ZSQ-8-3 (154 mg,0.25 mmol) and Pd/C (100 mg) were mixed in 10ml of methanol and stirred for 6h at room temperature. After the reaction was completed, the mixture was filtered through celite, washed with methanol, and the filtrate was concentrated and purified by reverse phase column chromatography on C18, eluting with H 2O/CH3 CN (1:7), to give 116mg of the product as a yellow oil in 90% yield
Synthesis of tert-butyl (ZSQ-8-8) carbamate, the compound (5- ((3- ((4- (1, 3, 2-dithioarsine pent-2 yl) phenyl) carbamoyl) benzyl) amino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) (benzyl)
ZSQ-8-6 (116 mg,0.22 mmol) and ZSQ-1-23 (70 mg,0.27 mmol) were dissolved in 3ml of dry pyridine, the mixed solution was stirred at 0deg.C, phosphorus oxychloride (42 ul,0.45 mmol) was added dropwise to the mixed solution (over 10 min), stirring was continued at 0deg.C for 1h after the addition was completed, and then the solution was moved to room temperature and stirred for 2h. After the completion of the reaction, the mixture was acidified with a dilute hydrochloric acid solution, washed with water (30 ml. Times.3), extracted with EA and washed with a saturated sodium chloride solution. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica gel eluting with PE/EA (4:1) to give the pyridinium salt, followed by DCM/CH 3OH(NH3) (10:1) gave 92mg as a yellow powder in 54% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -3- (((7- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino) methyl) benzamide (ZSQ-8-9)
ZSQ-8-8 (92 mg,0.12 mmol) and 0.5ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:7), to give 64.8mg of a white solid in 82% yield.
Synthesis of Compound (4- (3- (((7- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino) methyl) benzoylamino) phenyl) arsinic acid (ZSQ-8-12)
ZSQ-8-9 (64.8 mg,0.099 mmol), mercuric perchlorate trihydrate (33 mg,0.074 mmol) was dissolved in 2ml DMSO, the mixed solution was stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 45mg of white powder in 76% yield.
Example 6
Synthetic route to Compounds ZSQ-9-73
Synthesis of tert-butyl (ZSQ-9-48) piperidine-1-carboxylate as Compound (R) -3- ((7- (benzyl (tert-butoxycarbonyl) amino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino)
Compounds ZSQ-7-94 (200 mg,0.5 mmol), (R) -1-Boc-3-aminopiperidine (110 mg,0.55 mmol), tris (dibenzylideneacetone) dipalladium (23 mg,0.025 mmol), 1 '-binaphthyl-2, 2' -bisdiphenylphosphine (47 mg,0.075 mmol) and sodium tert-butoxide (53 mg,0.55 mmol) were mixed in 2ml toluene and heated to 95℃under nitrogen atmosphere and stirred for 16h. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3), extracted with EA (40 ml) and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (3:1) to give 242.5mg of a reddish brown solid in 85% yield.
Synthesis of the Compound (R) -N 7 -benzyl-3-isopropyl-N 5 - (piperidin-3-yl) pyrazolo [1,5-a ] pyrimidine-5, 7-diamine (ZSQ-9-55)
ZSQ-9-48 (242 mg,0.43 mmol) and 0.8ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:5), to give 150mg of a white solid in 96% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((7- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino) piperidin-1-yl) acetamide (ZSQ-9-60)
ZSQ-9-55 (150 mg,0.41 mmol), DIPEA (0.20 ml,1.23 mmol) and ZSQ-5-4 (155 mg,0.41 mmol) were dissolved in 7ml THF at room temperature and the mixture was stirred at room temperature for 3h. Then washed with 2N dilute hydrochloric acid solution (20 ml) and extracted with EA (3X 30 ml), followed by washing with water (2X 20 ml). The combined organic phases were dried over Na 2SO4, filtered and concentrated under reduced pressure, separated and purified by column chromatography on silica gel eluting with PE/EA (1:1) to give 133.3mg of a yellow solid in 49% yield.
Synthesis of Compound (R) - (4- (2- (3- ((7- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-5-yl) amino) piperidin-1-yl) acetamido) phenyl) arsinic acid (ZSQ-9-73)
ZSQ-8-9 (66 mg,0.1 mmol) of mercury perchlorate trihydrate (36 mg,0.08 mmol) was dissolved in 2ml of DMSO, the mixed solution was stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 49.5mg of a yellow solid in 82% yield.
Example 7
Synthetic route to Compounds ZSQ-10-98
Synthesis of tert-butyl carbamate (ZSQ-7-71) of Compound (3- ((4- (1, 3, 2-dithioarsine pent-2-yl) phenyl) carbamoyl) benzyl)
ZSQ-1-23 (1.03 g,4 mmol), 3- (N-Boc-aminomethyl) benzoic acid (1.00 g,4 mmol), HATU (3.04 g,8 mmol) and DIPEA (1.98 ml,12 mmol) were dissolved in 20ml DCM and left to stir at room temperature for 4h. After the reaction was completed, it was washed with H 2 O (20 ml. Times.2), saturated NaCl solution (20 ml), extracted with 20ml DCM, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography, eluting with PE/EA (4:1) to give 990mg of pale yellow powder in 50% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -3- (aminomethyl) benzamide (ZSQ-7-75)
ZSQ-7-71 (990 mg,2.01 mmol) and 1ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction solution was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:5), to give 651mg of a white solid in 82% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -3- (((5-chloro-3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) amino) methyl) benzamide (ZSQ-10-91)
ZSQ-7-88 (318 mg,1.39 mmol), DIPEA (0.46 ml,2.78 mmol) and ZSQ-7-75 (544 mg,1.39 mmol) were dissolved in 6ml absolute ethanol, heated to 85℃and stirred overnight. After completion of the reaction, the reaction mixture was concentrated, washed with water (30 ml. Times.2), extracted with EA (30 ml), and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography on silica gel eluting with PE/EA (5:1) to give 588mg of brown solid in 72% yield.
Synthesis of tert-butyl (ZSQ-10-92) carbamate of Compound (3- ((4- (1, 3, 2-dithioarsin-2-yl) phenyl) carbamoyl) benzyl) (5-chloro-3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl)
ZSQ-10-91 (588 mg,1 mmol), 4-dimethylaminopyridine (24 mg,0.2 mmol) and di-tert-butyl dicarbonate (300 ul,1.3 mmol) were mixed and dissolved in 5ml THF and stirred at room temperature for 12h. After completion of the reaction, the reaction mixture was washed with H 2 O (20 ml. Times.2), extracted with EA (30 ml) and washed with saturated sodium hydrogencarbonate solution (30 ml). The organic phase was dried over anhydrous sodium sulfate, concentrated by filtration and purified by column chromatography on silica gel eluting with PE/EA (7:1) to give 524mg of yellow solid in 76% yield.
Synthesis of tert-butyl (ZSQ-10-93) carbamate of the compound (3- ((4- (1, 3, 2-dithioarsen-2-yl) phenyl) carbamoyl) benzyl) (5- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl)
Compounds ZSQ-10-93 (274 mg,0.4 mmol), benzylamine (52 ul,0.48 mmol), tris (dibenzylideneacetone) dipalladium (18 mg,0.02 mmol), 1 '-binaphthyl-2, 2' -bisdiphenylphosphine (37 mg,0.06 mmol) and sodium t-butoxide (46 mg,0.48 mmol) were mixed in 2ml toluene and heated to 95℃under nitrogen atmosphere and stirred for 16h. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3), extracted with EA (40 ml) and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (3:1) to give 40mg of a white powder in 13% yield.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -3- (((5- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) amino) methyl) benzamide (ZSQ-10-95)
ZSQ-10-93 (40 mg,0.05 mmol) and 0.5ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:7), to give 23mg of a white solid in 69% yield.
Synthesis of Compound (4- (3- (((5- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) amino) methyl) benzoylamino) phenyl) arsinic acid (ZSQ-10-98)
ZSQ-10-95 (23 mg,0.035 mmol), mercury perchlorate trihydrate (12 mg,0.028 mmol) was dissolved in 2ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 17mg of a white solid in 85% yield.
Example 8
Synthetic route to Compound ZSQ-12-3
Synthesis of tert-butyl (ZSQ-11-64) piperidine-1-carboxylate, a compound (R) -3- ((5-chloro-3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) amino)
ZSQ-7-88 (345 mg,1.5 mmol), DIPEA (0.49 ml,3.0 mmol) and (R) -1-Boc-3-aminopiperidine (450 mg,2.25 mmol) were dissolved in 6ml absolute ethanol, heated to 85℃and stirred overnight. After completion of the reaction, the reaction mixture was concentrated, washed with water (30 ml. Times.2), extracted with EA (30 ml), and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography on silica gel eluting with PE/EA (4:1) to give 571mg of white powder in 96% yield.
Synthesis of tert-butyl (ZSQ-11-89) piperidine-1-carboxylate, the compound (R) -3- ((tert-butoxycarbonyl) (5-chloro-3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) amino)
ZSQ-10-64 (571 mg,1.45 mmol), 4-dimethylaminopyridine (35 mg,0.20 mmol) and di-tert-butyl dicarbonate (433 ul,1.89 mmol) were mixed and dissolved in 6ml THF and stirred at room temperature for 12h. After completion of the reaction, the reaction mixture was washed with H 2 O (20 ml. Times.2), extracted with EA (30 ml) and washed with saturated sodium hydrogencarbonate solution (30 ml). The organic phase was dried over anhydrous sodium sulfate, concentrated by filtration and purified by column chromatography on silica gel eluting with PE/EA (8:1) to give 670mg of a white solid in 93% yield.
Synthesis of tert-butyl Compound (R) -3- ((5- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) (tert-butoxycarbonyl) amino) piperidine-1-carboxylate (ZSQ-11-94)
Compounds ZSQ-11-89 (495 mg,1.0 mmol), benzylamine (131 ul,1.2 mmol), tris (dibenzylideneacetone) dipalladium (46 mg,0.05 mmol), 1 '-binaphthyl-2, 2' -bisdiphenylphosphine (93 mg,0.15 mmol) and sodium t-butoxide (115 mg,1.2 mmol) were mixed in 5ml toluene and heated to 95℃under nitrogen atmosphere and stirred for 16h. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3), extracted with EA (40 ml) and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (3:1) to give 524mg of a reddish brown solid in 93% yield.
Synthesis of the Compound (R) -N 5 -benzyl-3-isopropyl-N 7 - (piperidin-3-yl) pyrazolo [1,5-a ] pyrimidine-5, 7-diamine (ZSQ-11-96)
ZSQ-11-94 (524 mg,0.93 mmol) and 1ml trifluoroacetic acid were mixed in 6ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:5), to give 322mg of a white solid in 95% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) amino) piperidin-1-yl) acetamide (ZSQ-11-104)
ZSQ-11-96 (182 mg,0.5 mmol), K 2CO3 (166 mg,1.2 mmol) and ZSQ-5-4 (190 mg,0.5 mmol) were dissolved in 4ml CH 3 CN solution at room temperature and the mixed solution was stirred at room temperature for 4h. Then washed with 2N dilute hydrochloric acid solution (20 ml) and extracted with EA (3X 30 ml), followed by washing with water (2X 20 ml). The combined organic phases were dried over Na 2SO4, filtered and concentrated under reduced pressure, purified by column chromatography on silica gel eluting with DCM/EA (4:1) to give 205mg of a white powder in 62% yield.
Synthesis of Compound (R) - (4- (2- (3- ((5- (benzylamino) -3-isopropylpyrazolo [1,5-a ] pyrimidin-7-yl) amino) piperidin-1-yl) acetamido) phenyl) arsinic acid (ZSQ-12-3)
ZSQ-11-104 (66 mg,0.10 mmol), mercury perchlorate trihydrate (36 mg,0.08 mmol) was dissolved in 3ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 49mg of a white solid in 81% yield.
Example 9
Synthetic route to compound ZSQ-13-92
Synthesis of Compound 3- (2-chloro-5-iodopyrimidin-4-yl) -1H-indole (ZSQ-12-59)
Methyl magnesium bromide (1M in tetrahydrofuran, 70ml,70 mmol) was added dropwise to a solution of indole (8.26 g,70 mmol) in THF (50 ml) at 0deg.C over 30min. The solution was stirred for a further 30min at 0 ℃.2, 4-dichloro-5-iodopyrimidine (2.74 g,35 mmol) was added dropwise to give a yellow solution. The ice bath was removed and the solution was stirred at room temperature for 1h to give a red solution. The mixed solution was warmed to 60 ℃ and stirred for an additional 1.5h. The mixture was cooled to room temperature and acetic acid (70 ml) was added dropwise. Water (70 ml) and THF (30 ml) were added, and the mixture was stirred at 60℃for 20min to give a two-phase solution. Layering and adding petroleum ether (100 ml) to the organic solution resulted in crystallization of the solid. The solid was collected by filtration, washed with petroleum ether (20 ml) and dried under vacuum to give 2.5g of a yellow solid in 20% yield.
Synthesis of Compound 3- (2-chloro-5-iodopyrimidin-4-yl) -1- (phenylsulfonyl) -1H-indole (ZSQ-13-76)
ZSQ-13-59 (1.06 g,3 mmol), naOH (180 mg,4.5 mmol) and Bu 4NHSO4 (871 mg,1.5 mmol) were dissolved in 20ml DCM and benzenesulfonyl chloride (576 ul,4.5 mmol) was added dropwise at room temperature. The reaction mixture was stirred at room temperature for a further 4h. The mixture was quenched with water (30 ml) and extracted with DCM (20 ml. Times.3). The combined organic layers were dried over anhydrous Na 2SO4, filtered, concentrated, and purified by column chromatography on silica gel eluting with DCM/EA (4:1) to give 850mg of a white solid in 57% yield.
Synthesis of Compound 3- (2-chloro-5- ((trimethylsilyl) ethynyl) pyrimidin-4-yl) -1- (phenylsulfonyl) -1H-indole (ZSQ-13-77)
Compounds ZSQ-13-76 (850 mg,1.72 mmol), trimethylsilylacetylene (264 ul,2.58 mmol), cuprous iodide (32 mg,0.17 mmol), 1' -bis-diphenylphosphino ferrocene palladium dichloride (73 mg,0.10 mmol) and triethylamine (178 ul,3.44 mmol) were mixed in 10ml of dry tetrahydrofuran solution and heated to 50℃under nitrogen atmosphere and stirred for 12h. After completion of the reaction, the reaction mixture was washed with 2M dilute hydrochloric acid (30 ml. Times.2), extracted with DCM (50 ml), and washed successively with water (30 ml) and saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (4:1) to give 380mg of white solid in 47% yield.
Synthesis of tert-butyl (ZSQ-13-86) piperidine-1-carboxylate (R) -3- ((4- (1- (phenylsulfonyl) -1H-indol-3-yl) -5- ((trimethylsilyl) ethynyl) pyrimidin-2-yl) amino)
ZSQ-13-77 (380 mg,0.817 mmol), (R) -1-Boc-3-aminopiperidine (172 mg,0.858 mmol) and DIPEA (0.4 ml, 2.457 mmol) were mixed and dissolved in 3ml N-methylpyrrolidone. The mixed solution was heated at 135℃and stirred for 3h. The cooled solution was directly purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:9) to give 448mg of brown powder in 87% yield.
Synthesis of the Compound (R) -5-ethynyl-4- (1- (phenylsulfonyl) -1H-indol-3-yl) -N- (piperidin-3-yl) pyrimidin-2-amine (ZSQ-13-87)
/>
ZSQ-13-86 (4478 mg,0.71 mmol) and 1ml trifluoroacetic acid were mixed in 6ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:5), to give 105mg of a tan solid in 32% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-ethynyl-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamide (ZSQ-13-88)
ZSQ-13-87 (105 mg,0.23 mmol), DIPEA (0.11 ml,0.69 mmol) and ZSQ-5-4 (91 mg,0.24 mmol) were dissolved in 4ml THF at room temperature and the mixture stirred at room temperature for 4h. Then washed with 2N dilute hydrochloric acid solution (20 ml) and extracted with EA (3X 30 ml), followed by washing with water (2X 20 ml). The combined organic phases were dried over Na 2SO4, filtered and concentrated under reduced pressure, purified by column chromatography on silica gel eluting with DCM/EA (2:1) to give 75mg of a white powder in 43% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-ethynyl-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamide (ZSQ-13-91)
ZSQ-13-88 (75 mg,0.1 mmol) of anhydrous potassium carbonate (41 mg,0.3 mmol) was dissolved in a mixed solution of 2ml of anhydrous methanol and 2ml of anhydrous THF, and the mixture was stirred at room temperature for 4 hours. After the reaction was completed, the pH was adjusted to weak acidity with TFA, and the reaction mixture was directly purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:6), to give 52mg of a yellow powder in 85% yield.
Synthesis of Compound (R) - (4- (2- (3- ((5-ethynyl-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamido) phenyl) arsinic acid (ZSQ-13-92)
ZSQ-13-91 (52 mg,0.08 mmol), mercuric perchlorate trihydrate (30 mg,0.06 mmol) was dissolved in 3ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 40mg of a yellow solid in 88% yield.
Example 10
Synthetic route to Compound ZSQ-14-23
Synthesis of the Compound 4- (1, 3, 2-dithioarsin-2-yl) -N- (prop-2-yn-1-yl) aniline (ZSQ-14-7)
Compounds ZSQ-1-23 (1.03 mg,4 mmol), 3-bromopropyne (379 ul,4.4 mmol) and anhydrous potassium carbonate (829 mg,6.0 mmol) were mixed in 8ml DMF and stirred at room temperature for 12h. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3) and extracted with EA (30 ml). The organic phase was dried over anhydrous sodium sulfate, concentrated by filtration and purified by column chromatography on silica gel eluting with PE/EA (7:1) to give 850mg of yellow solid in 72% yield
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2-bromo-N- (prop-2-yn-1-yl) acetamide (ZSQ-14-10)
ZSQ-14-7 (850 mg,2.86 mmol) and DIPEA (7.15 ml,3.14 mmol) were dissolved in 20ml of dry DCM and stirred at 0deg.C. Bromoacetyl bromide (0.27 ml,3.14 mmol) was added dropwise over 15min and stirring was continued for 1h at 0 ℃. The mixture was diluted with DCM (20 ml), washed with 2N diluted hydrochloric acid solution (30 ml), water (50 ml), saturated sodium bicarbonate solution (30 ml), saturated brine (30 ml) and dried over anhydrous sodium sulfate, and the solvent was removed by filtration. Purification by column chromatography on silica eluting with PE/EA (1:4) afforded 338mg as a yellow solid in 28% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) -N- (prop-2-yn-1-yl) acetamide (ZSQ-14-13)
ZSQ-14-10 (93 mg,0.20 mmol), DIPEA (0.10 ml,0.60 mmol) and ZSQ-5-4 (88 mg,0.21 mmol) were dissolved in 2ml THF at room temperature and the mixed solution stirred at room temperature for 4h. Then washed with 2N dilute hydrochloric acid solution (20 ml) and extracted with EA (3X 30 ml), followed by washing with water (2X 20 ml). The combined organic phases were dried over Na 2SO4, filtered and concentrated under reduced pressure, purified by column chromatography on silica gel eluting with DCM/EA (3:1) to give 95mg of a yellow solid in 59% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) -N- (prop-2-yn-1-yl) acetamide (ZSQ-14-18)
ZSQ-14-13 (95 mg,0.12 mmol) of anhydrous potassium carbonate (66 mg,0.48 mmol) was dissolved in a mixed solution of 2ml of anhydrous methanol and 2ml of anhydrous THF, and the mixture was stirred at room temperature for 4 hours. After the completion of the reaction, pH was adjusted to weak acidity with TFA, and the reaction mixture was directly purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:5), to give 50mg of a yellow powder in 63% yield.
Synthesis of Compound (R) - (4- (2- (3- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) -N- (prop-2-yn-1-yl) acetamido) phenyl) arsinic acid (ZSQ-14-23)
ZSQ-14-18 (50 mg,0.07 mmol), mercuric perchlorate trihydrate (27 mg,0.06 mmol) was dissolved in 3ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 35mg of a yellow solid in 83% yield.
Example 11
Synthetic route to Compound ZSQ-15-99
Synthesis of Compound 2-formylbutyronitrile (ZSQ-14-104)
2M lithium diisopropylamide solution (27.5 ml,55 mmol) was mixed in 50ml dry THF, stirred at-78℃and butyronitrile (4.35 ml,50 mmol) was added dropwise, stirring continued for 30min after addition was completed, ethyl formate (4.85 ml,60 mmol) was mixed in 25ml dry THF, added dropwise to the mixed solution at-78℃over 30min, stirring continued for 45min after addition was continued and then brought to room temperature, stirred for 14h. After completion of the reaction, 10ml of H 2 O was added to quench the reaction mixture, the mixture was concentrated, diluted hydrochloric acid solution was added to adjust pH to 3, then extracted with EA (20 ml. Times.3), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and dried by suction to give 4.82g of a crude product as a yellow oil
Synthesis of the Compound 4-ethyl-1H-pyrazol-3-amine (ZSQ-15-1)
ZSQ-14-104 (4.82 g,49.6 mmol), hydrazine hydrate (3.61 ml,74.4 mmol) and acetic acid (5.67 ml,99.2 mmol) were mixed in 75ml absolute ethanol, heated in a closed tube and stirred for 16h. After completion of the reaction, the mixture was concentrated to leave 1/3, washed with saturated sodium bicarbonate solution (40 ml) (pH was adjusted to alkaline), extracted with DCM (30 ml. Times.2), and washed with saturated sodium chloride solution (40 ml). The combined organic phases were dried over anhydrous sodium sulfate, and the filtrate was concentrated to dryness without further purification to give 4.88g of a yellow solid.
Synthesis of the Compound 3-ethylpyrazolo [1,5-a ] pyrimidine-5, 7-diol (ZSQ-15-2)
ZSQ-15-1 (4.88 g,43 mmol) was dissolved in a sealed tube containing 80ml of dry ethanol, 20% sodium ethoxide solution (16 g,47.5 mmol) was added, the mixed solution was heated to reflux temperature and stirred for 22h. After the completion of the reaction, the reaction mixture was concentrated, diluted with water (50 ml), adjusted to pH 3 with a dilute hydrochloric acid solution, and a large amount of solids were precipitated, filtered and washed with water several times. A yellow powder was obtained, and after drying, 2.98g of a white powder was obtained.
Synthesis of the Compound 5, 7-dichloro-3-ethylpyrazolo [1,5-a ] pyrimidine (ZSQ-15-4)
ZSQ-15-2 (2.98 g,16.6 mmol) and N, N-dimethylaniline (250 ul,2.01 mmol) were mixed in a sealed tube containing 45ml of phosphorus oxychloride, heated to 115℃overnight and stirred under reflux. After completion of the reaction, the mixed solution was concentrated, the remaining solution was dropwise added to ice water, extracted with DCM a plurality of times, washed with saturated sodium chloride solution (30 ml), and the organic phases were combined. Drying over anhydrous sodium sulfate, filtering, concentrating, separating and purifying by silica gel column chromatography, eluting with PE/EA (5:1) to obtain white needle-like powder 2.33g, with a yield of 65%.
Synthesis of the Compound 5-chloro-3-ethyl-N- (4-methoxybenzyl) pyrazolo [1,5-a ] pyrimidin-7-amine (ZSQ-15-72)
ZSQ-15-4 (433 mg,2.0 mmol), DIPEA (4.96 ml,3.0 mmol) and 4-methoxybenzylamine (0.52 ml,4.0 mmol) were dissolved in 8ml absolute ethanol, heated to 85℃and stirred overnight. After completion of the reaction, the reaction mixture was concentrated, washed with water (30 ml. Times.2), extracted with EA (30 ml), and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography on silica gel eluting with PE/EA (5:1) to give 631mg of white solid in 99% yield.
Synthesis of tert-butyl (ZSQ-15-74) carbamate, the compound (5-chloro-3-ethylpyrazolo [1,5-a ] pyrimidin-7-yl) (4-methoxybenzyl)
ZSQ-15-72 (8231 mg,2 mmol), 4-dimethylaminopyridine (48 mg,0.4 mmol) and di-tert-butyl dicarbonate (598 ul,2.6 mmol) were mixed and dissolved in 8ml THF and stirred at room temperature for 12h. After completion of the reaction, the reaction mixture was washed with H 2 O (20 ml. Times.2), extracted with EA (30 ml) and washed with saturated sodium hydrogencarbonate solution (30 ml). The organic phase was dried over anhydrous sodium sulfate, concentrated by filtration and purified by column chromatography on silica gel eluting with PE/EA (8:1) to give 830mg of a yellow solid in 99% yield.
Synthesis of tert-butyl (ZSQ-15-83) carbamate, the compound (3-ethyl-5- (2- (2-hydroxyethyl) piperidin-1-yl) pyrazolo [1,5-a ] pyrimidin-7-yl) (4-methoxybenzyl)
Compounds ZSQ-15-74 (416 mg,1.0 mmol), 2-piperidineethanol (165 mg,1.0 mmol), tris (dibenzylideneacetone) dipalladium (46 mg,0.05 mmol), 1 '-binaphthyl-2, 2' -bisdiphenylphosphine (93 mg,0.15 mmol) and sodium t-butoxide (106 mg,1.1 mmol) were mixed in 3ml toluene and heated to 95℃under nitrogen atmosphere and stirred for 16h. After completion of the reaction, the reaction mixture was washed with H 2 O (30 ml. Times.3), extracted with EA (40 ml) and washed with a saturated sodium chloride solution (30 ml). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (8:1) to give 350mg of red solid in 68% yield.
Synthesis of Compound 2- (1- (7-amino-3-ethylpyrazolo [1,5-a ] pyrimidin-5-yl) piperidin-2-yl) ethan-1-ol (ZSQ-15-97)
Compound ZSQ-15-97 (283 mg,0.69 mmol) was dissolved in a mixture of 2ml concentrated hydrochloric acid and 2ml DCM and stirred at room temperature for 6h. After the reaction was completed, the reaction solution was concentrated, separated and purified by silica gel column chromatography, eluting with DCM/CH 3OH(NH3 (5:1) to give 115mg of a white solid with a yield of 57%.
Synthesis of the Compound N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- ((3-ethyl-5- (2- (2-hydroxyethyl) piperidin-1-yl) pyrazolo [1,5-a ] pyrimidin-7-yl) amino) acetamide (ZSQ-15-98)
ZSQ-15-97 (115 mg,0.4 mmol), potassium carbonate (138 mg,1.0 mmol), potassium iodide (33 mg,0.2 mmol) and ZSQ-5-4 (228 mg,0.6 mmol) were dissolved in 1.5ml CH 3 CN/1.5ml DMF at room temperature, and the mixed solution was stirred at room temperature for 4h. Acidification with TFA followed by separation and purification by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:9) afforded 153mg of a pink solid in 65% yield.
Synthesis of Compound (4- (2- ((3-ethyl-5- (2- (2-hydroxyethyl) piperidin-1-yl) pyrazolo [1,5-a ] pyrimidin-7-yl) amino) acetamido) phenyl) arsinic acid (ZSQ-15-99)
ZSQ-15-98 (50 mg,0.10 mmol), mercuric perchlorate trihydrate (36 mg,0.08 mmol) was dissolved in 2ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 28mg of a yellow solid in 53% yield.
Example 12
Synthetic route to Compound ZSQ-14-66
Synthesis of isopropyl (2-nitrophenyl) sulfane (ZSQ-14-27) compound
1-Fluoro-2-nitrobenzene (14 g,100 mmol), isopropyl mercaptan (10.2 ml,110 mmol), anhydrous potassium carbonate (27.6 g,200 mmol) were mixed and dissolved in 100ml anhydrous DMF and stirred at 110℃for 12h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, washed with 100ml of water, 100ml of saturated sodium chloride solution, and extracted with EA. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica gel eluting with PE/EA (7:1) afforded 18g as a yellow oil with 91% yield.
Synthesis of Compound 1- (isopropylsulfonyl) -2-nitrobenzene (ZSQ-14-35)
Compound ZSQ-14-27 (9.85 g,50 mmol) was dissolved in 100ml methanol and stirred at 0deg.C. Potassium peroxomonosulphonate (15.37 g,250 mmol) was dissolved in 100ml of water and added dropwise to the mixture at 0℃and after the addition was completed, stirring was continued at 0℃for 1h and then the mixture was allowed to stand at room temperature for 24h. After completion of the reaction, methanol was distilled off under reduced pressure, and then washed with 50ml of water, 50ml of a saturated sodium chloride solution, and extracted with EA. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give 8.3g of a bright yellow oily liquid in 72% yield.
Synthesis of Compound 2- (isopropylsulfonyl) aniline (ZSQ-14-48)
Compound ZSQ-14-35 (2.29 g,10 mmol) was dissolved in 20ml methanol, pd/C (200 mg) was added and stirred at room temperature under a hydrogen atmosphere for 12h. After completion of the reaction, it was filtered through celite and washed with DCM. The filtrate was concentrated and pumped down by an oil pump to give 1.99g of a white solid with a yield of 99%.
Synthesis of Compound 2, 5-dichloro-N- (2- (isopropylsulfonyl) phenyl) pyrimidin-4-amine (ZSQ-14-49)
NaH (600 mg,15 mmol) was dissolved in dry 60ml DMF and stirred at 0deg.C. ZSQ-14-48 (1.99 g,10 mmol) was dissolved in 5ml of dry DMF and added dropwise to the above mixed solution (over 10 min). After the addition was completed and stirring was continued at 0℃for 0.5 hours, 2,4, 5-trichloropyrimidine (2.29 ml,20 mmol) was added dropwise, and after stirring for 1 hour, it was allowed to move to room temperature overnight and stirred. After the completion of the reaction, 20ml of water was added thereto, and DMF was removed by concentration under reduced pressure. This was washed successively with 100ml of water, 100ml of saturated sodium bicarbonate solution, 100ml of saturated sodium chloride solution, and extracted with EA. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica gel eluting with PE/EA (3:1) afforded 1.2g of a white solid in 35% yield.
Synthesis of tert-butyl (ZSQ-14-54) piperidine-1-carboxylate, a compound (R) -3- ((5-chloro-4- ((2- (isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)
ZSQ-14-49 (173 mg,0.5 mmol), (R) -1-Boc-3-aminopiperidine (100 mg,0.5 mmol) and DIPEA (248 ul,1.5 mmol) were mixed and dissolved in 2ml N-methylpyrrolidone. The mixed solution was heated at 135℃and stirred for 3h. The cooled solution was directly purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:9) to give 232mg of a pale yellow solid in 91% yield.
Synthesis of Compound (R) -5-chloro-N 4 - (2- (isopropylsulfonyl) phenyl) -N 2 - (piperidin-3-yl) pyrimidine-2, 4-diamine (ZSQ-14-58)
ZSQ-14-54 (232 mg,0.45 mmol) and 1ml trifluoroacetic acid were mixed in 5ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (3:1), to give 180mg of a pale yellow solid in 97% yield.
Synthesis of the Compound (R) -N- (4- (1, 3, 2-dithioarsin-2-yl) phenyl) -2- (3- ((5-chloro-4- ((2- (isopropyl-sulfonyl) phenyl) amino) pyrimidin-2-yl) amino) piperidin-1-yl) acetamide (ZSQ-14-60)
ZSQ-14-58 (82 mg,0.2 mmol), DIPEA (0.13 ml,0.8 mmol) and ZSQ-5-4 (76 mg,0.2 mmol) were dissolved in 3ml THF at room temperature and the mixture stirred at room temperature for 4h. Then washed with 2N dilute hydrochloric acid solution (20 ml) and extracted with EA (3X 30 ml), followed by washing with water (2X 20 ml). The combined organic phases were dried over anhydrous Na 2SO4, filtered and concentrated under reduced pressure, separated and purified by column chromatography on silica gel eluting with DCM/EA (3:1) to give 79mg of a yellow solid in 56% yield.
Synthesis of Compound (R) - (4- (2- (3- ((5-chloro-4- ((2- (isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino) piperidin-1-yl) acetamido) phenyl) arsinic acid (ZSQ-14-66)
ZSQ-14-60 (36 mg,0.05 mmol), mercuric perchlorate trihydrate (18 mg,0.04 mmol) was dissolved in 2ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:3) to give 24mg of a yellow solid in 75% yield.
Synthesis scheme 13
Synthetic route to Compound ZSQ-16-91
Synthesis of Compound (4-hydroxy-3-nitrophenyl) arsinic acid (ZSQ-16-8)
3-Nitro-4-hydroxyphenylarsonic acid (26.3 g,100 mmol) was dissolved in 80ml methanol and the mixed solution was heated to reflux. Phenylhydrazine (19.6 ml,200 mol) was added dropwise (over 1 h), with a large amount of nitrogen being generated during the addition, and reflux stirring was continued for 1.5h when nitrogen generation was slowed down. The mixture was concentrated by distillation under reduced pressure, and sodium hydroxide solution (12 g in 200ml of water) and 200ml of diethyl ether were added. The mixture was separated, and a 2N diluted hydrochloric acid solution (100 ml) was added to the aqueous phase and stirred for 1h, followed by extraction with EA (200 ml. Times.3). The organic phase was dried over anhydrous sodium sulfate, concentrated, pumped out by an oil pump, and the next reaction was carried out without purification.
Synthesis of Compound 4- (1, 3, 2-dithioarsin-2-yl) -2-nitrophenol (ZSQ-16-14)
ZSQ-16-8 (24.7 g,100 mmol) was dissolved in 100ml methanol and heated to reflux. Then, ethanedithiol (10 ml,120 mmol) was added dropwise to the mixed solution over 30min, and heating and stirring were continued for 30min. The mixed solution was then concentrated, separated and purified by column chromatography on silica gel eluting with PE/EA (10:1) to give a crude yellow solid. Dissolution with THF and further purification by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (8:1) afforded 9g of the product as a yellow solid in 29.5% yield.
Synthesis of Compound 2-amino-4- (1, 3, 2-dithioarsin-2-yl) phenol (ZSQ-16-90)
ZSQ-16-14 (9.3 g,30 mmol) was dissolved in a mixed solution of ethanol/ethyl acetate (10:1, 100 ml), stannous chloride (13.5 g,60 mmol) was added and the mixed solution was stirred at 75℃under reflux for 48h. After completion of the reaction, the reaction mixture was concentrated, washed with water (100X 3 ml), and extracted with EA (100 ml). The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography on silica gel eluting with PE/EA (8:1) to give 340mg of crude yellow solid in 4% yield.
Synthesis of tert-butyl (ZSQ-16-1) carbamate, a compound (5- (1, 3, 2-dithioarsin-2-yl) -2-hydroxyphenyl)
ZSQ-16-90 (120 mg,0.72 mmol) and di-tert-butyl dicarbonate (200 ul,0.87 mmol) were mixed and dissolved in 4ml THF and stirred at room temperature for 24h. After completion of the reaction, the reaction mixture was washed with H 2 O (50 ml. Times.2) and extracted with EA (50 ml). The organic phase was dried over anhydrous sodium sulfate, concentrated by filtration and purified by column chromatography on silica gel eluting with PE/EA (6:1) to give 120mg of a white solid in 43% yield.
Synthesis of tert-butyl Compound (5- (1, 3, 2-dithioarsin-2-yl) -2-methoxyphenyl) carbamate (ZSQ-16-68)
Compound ZSQ-16-1 (120 mg,0.32 mmol), methyl iodide (24 ul,0.38 mmol), anhydrous potassium carbonate (88 mg,0.64 mmol), and potassium iodide (10 mg,0.06 mmol) were mixed in 2ml acetonitrile and stirred at room temperature. After the reaction is completed, the reaction solution is directly concentrated, separated and purified by silica gel column chromatography, and eluted by PE/EA (6:1) to obtain 90mg of white solid with the yield of 72 percent.
Synthesis of Compound 5- (1, 3, 2-dithioarsin-2-yl) -2-methoxyaniline (ZSQ-16-76)
ZSQ-16-68 (90 mg,0.23 mmol) and 0.3ml trifluoroacetic acid were mixed in 3ml DCM and stirred overnight at room temperature. After the completion of the reaction, the reaction mixture was concentrated and purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:6), to give 52mg of a white solid in 78% yield.
Synthesis of Compound N- (5- (1, 3, 2-dithioarsin-2-yl) -2-methoxyphenyl) -2-bromoacetamide (ZSQ-16-86)
ZSQ-16-76 (289 mg,1.0 mmol) and DIPEA (0.41 ml,2.5 mmol) were dissolved in 5ml of dry DCM and stirred at 0deg.C. Bromoacetyl bromide (0.1 ml,1.1 mmol) was added dropwise over 10min and stirring was continued at 0℃for 1h and then brought to room temperature for 2h. The mixture was diluted with DCM (20 ml), washed with water (50 ml), extracted with DCM, the organic phases combined, dried over anhydrous sodium sulfate, filtered and concentrated. Purification by column chromatography on silica eluting with PE/EA (5:1) afforded 110mg as a yellow solid in 27% yield.
Synthesis of the Compound (R) -N- (5- (1, 3, 2-dithioarsin-2-yl) -2-methoxyphenyl) -2- (3- ((5-chloro-4- (1- (phenylsulfonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamide (ZSQ-16-87)
ZSQ-16-68 (110 mg,0.26 mmol), DIPEA (0.13 ml,0.80 mmol) and ZSQ-5-4 (138 mg,0.29 mmol) were dissolved in 3ml THF at room temperature and the mixture was stirred at room temperature for 4h. Then washed with 2N dilute hydrochloric acid solution (20 ml) and extracted with EA (3X 30 ml), followed by washing with water (2X 20 ml). The combined organic phases were dried over Na 2SO4, filtered and concentrated under reduced pressure, separated and purified by column chromatography on silica gel eluting with DCM/EA (3:1) to give 177mg of a white solid powder in 83% yield.
Synthesis of the Compound (R) -N- (5- (1, 3, 2-dithioarsin-2-yl) -2-methoxyphenyl) -2- (3- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamide (ZSQ-16-88)
ZSQ-16-87 (177 mg,0.22 mmol) of anhydrous potassium carbonate (92 mg,0.66 mmol) was dissolved in a mixed solution of 1.5ml of anhydrous methanol and 1.5ml of anhydrous THF, and the mixture was stirred at room temperature for 4 hours. After the reaction was completed, the pH was adjusted to weak acidity with TFA, and the reaction mixture was directly purified by C18 reverse phase column chromatography, eluting with H 2O/CH3 CN (1:8), to give 121mg of a pale yellow solid in 84% yield.
Synthesis of Compound (R) - (3- (2- (3- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) piperidin-1-yl) acetamido) -4-methoxyphenyl) arsinic acid (ZSQ-16-91)
ZSQ-16-88 (66 mg,0.1 mmol), mercuric perchlorate trihydrate (36 mg,0.08 mmol) was dissolved in 2ml DMSO and the mixed solution stirred at room temperature for 10min, immediately purified by C18 reverse phase column chromatography eluting with H 2O/CH3 CN (1:5) to give 46mg of a yellow solid in 76% yield.
TABLE 1
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
Activity test example 1 CDK inhibitor test for growth inhibitory Activity against cancer cells
The adopted biological test scheme is as follows: effect of the compounds on cell growth activity of acute lymphoblastic leukemia cell line Jurkat and non-small cell lung cancer cell line H3122.
To verify the growth inhibitory effect of the compounds of the present invention on cancer cells at the cellular level, jurkat cells (hematological cancer, suspension type) and H3122 cells (solid tumor, adherent type) were selected, and cell viability was calculated by detecting chemiluminescent values, thereby obtaining the biological activity of the compounds to inhibit the growth of cancer cells.
The method comprises the following steps: jurkat or H3122 cells were cultured in vitro, grown to logarithmic growth phase, cells were collected, centrifuged at 1000rpm for 5min, the supernatant was discarded, the cell concentration was adjusted to 2.5X10 5/mL (Jurkat) or 1.5X10 5/mL (H3122), and cells were seeded into 384 well plates at 40. Mu.l per well. After adding 5. Mu.L of each of the compound or DMSO at different concentrations to the corresponding wells, and incubating in a cell incubator (37 ℃ C., 5% CO 2) for 72 hours, 15. Mu. L CELL TITER-Glo solution was added to each well, incubated at room temperature for 30 minutes, and the chemiluminescent value (luminescence) was measured to measure intracellular ATP levels. The unstimulated DMSO control wells were 100% cell viability. Compound IC 50 values were calculated using PRISM GRAPHPAD statistical software.
Table 2 CDK results of test for inhibition of growth inhibitory Activity of inhibitors on cancer cell lines
/>
Activity test example 2 CDK test of inhibitor for growth inhibitory Activity against non-Small cell Lung cancer cell lines
The adopted biological test scheme is as follows: influence of the Compounds on the growth activity of each of a plurality of non-small cell lung cancer cell lines.
To verify the growth inhibitory effect of representative compounds of the present invention on non-small cell lung cancer cell lines depending on the growth survival of different driving genes at the cellular level, H3122, H1299, H1975, H2077, H358, EBC-1, H23, PC9 and a549 cells were selected, respectively, and cell viability was calculated by detecting chemiluminescence values, thereby obtaining the biological activity of the compounds for inhibiting the growth of cancer cells, and comparing with the reported CDK inhibitors THZ1 and THZ 531.
The method comprises the following steps: various non-small cell lung cancer cells were cultured in vitro, grown to logarithmic growth phase, digested and collected, centrifuged at 1000rpm for 5min, the supernatant was discarded, the cell concentration was adjusted to 1.5X10 5/mL, and the cells were inoculated into 384-well plates, 40. Mu.l per well. After adding 5. Mu.L of each of the compound or DMSO at different concentrations to the corresponding wells, and incubating in a cell incubator (37 ℃ C., 5% CO 2) for 72 hours, 15. Mu. L CELL TITER-Glo solution was added to each well, incubated at room temperature for 30 minutes, and the chemiluminescent value (luminescence) was measured to measure intracellular ATP levels. The unstimulated DMSO control wells were 100% cell viability. Compound IC 50 values were calculated using PRISM GRAPHPAD statistical software.
Table 3 CDK results of test of inhibitor Activity against growth inhibition on different non-Small cell lung cancer cell lines
As can be seen from Table 3, the representative compounds of the present invention exhibited growth inhibitory activity comparable to or even better than THZ531 on various non-small cell lung cancer cell lines.
Activity test example 3 influence of CDK inhibitors on CDK7/12/13 kinase Activity in cancer cells
In various cancer cells, RNA polymerase II (Pol II) forms a transcription complex with transcription factors such as CDK7, 12, 13 and BRD4 through super enhancers, promotes high expression of oncogenes such as MYC, RUNX 1 and the like, and further maintains survival and proliferation of cancer cells. In the Pol II transcription complex, CDKs 7, 12, 13 are collectively responsible for sustained phosphorylation of the Ser5 site in the Pol II C-terminal domain (CTD) repeat sequence to ensure the normal initiation of the Pol II transcription procedure; CDKs 12, 13 are responsible for sustained phosphorylation of the Ser2 site in the Pol II CTD repeat to ensure proper transcription elongation process and DNA damage repair. Thus, when CDK12, 13 is inhibited simultaneously, the level of phosphorylation of the Ser2 site will be inhibited; when CDK7, 12, 13 is simultaneously inhibited, the level of phosphorylation of the Ser5 site will also be inhibited.
Experimental conditions and process: h3122 or A549 cells were cultured in vitro, after growth to logarithmic growth phase, the cells were digested and collected, centrifuged at 1000rpm for 5min, the supernatant was discarded, and the cell concentration was adjusted to 1X 10 6/mL. In a 12-well cell culture plate, 1ml of a DMSO solution of different concentrations of the drug was added to each well, THZ1, THZ531 or DMSO was used as a control, and after culturing in a cell incubator (37 ℃ C., 5% CO 2) for 8 hours, the cells were washed twice with a pre-chilled PBS solution, the solution was aspirated, 200. Mu.L of RIPA cell lysate, protease inhibitor and phosphatase inhibitor were added to the wells, transferred to a sample tube, and after shaking for 30 minutes at 4 ℃ C., centrifugation was performed at 15000rpm for 15 minutes at 4 ℃ C. And the supernatant was taken. Each group of proteins was assayed for content using BCA protein quantification kit and the amount of protein was adjusted using PIPA lysate to a final volume of 100 μl. And carrying out western-blot identification on the sample.
/>
Western-blot: to 100. Mu.L of the cell lysate was added 25. Mu.L of 5 Xprotein loading buffer and heated at 95℃for 10min. After the sample cooled, electrophoresis was performed using SDS-PAGE (9%) gel 60V, and after 30min, switching to 120V until the leading band was run to the bottom of the gel. Using a turbo semi-dry transfer system, constant current 0.2A was transferred for 80 minutes, and proteins in the gel were transferred to a PC membrane with a pore size of 0.2. Mu.L. The transferred PC membrane was blocked with 5% nonfat milk powder (TBST solution) for 2h and incubated with the corresponding primary antibody for 12h at 4 ℃. TBST was washed 3 times for 10min each. Incubate with the corresponding secondary antibody for 2h at room temperature. TBST was washed three times for 10min each. The ECL luminescence was used to incubate and detect the luminescence signal.
FIG. 1 shows the effect of representative compounds on Ser2 and Ser5 site phosphorylation of Pol II in H3122 (A) or A549 (B) cells. The experimental results show that:
ZSQ5-38, ZSQ8-36, ZSQ9-75 and other compounds can effectively inhibit the phosphorylation of the Ser2 site but not the Ser5 site at a concentration of 1. Mu.M;
ZSQ5-38, ZSQ17-22, etc. exhibit inhibitory activity superior to THZ 531;
THZ1 inhibits phosphorylation at both sites.
This suggests that ZSQ-38, ZSQ8-36, ZSQ9-75, and the like compounds are effective in inhibiting kinase activity of CDK12, 13 in cancer cells, but not CDK7.
Activity test example 4 irreversible binding of CDK inhibitor to CDK in H3122 cells
In this example, the CDK inhibitors of the invention are tested for irreversible binding to CDK7, 12 or 13.
Covalent inhibitors such as THZ1 or THZ531 are capable of forming covalent bonds with specific cysteine residues in the CDK7, 12 or 13 binding pocket and thereby irreversibly bind to CDK7, 12 or 13. THZ1-biotin has been reported to be a derivative of THZ1 and also to form covalent bonds with CDKs 7, 12 and 13 in cell lysates, and CDKs 7, 12 and 13 can be enriched by streptavidin microbeads (STREPTAVIDIN BEADS). When the THZ1, THZ531 or ZSQ series CDK inhibitor binds irreversibly to CDK7, 12 or 13, THZ1-biotin cannot bind to CDK7, 12 or 13 any more because the binding pocket is occupied. Thus, based on competition enrichment experiments of THZ1-biotin and streptavidin microbeads, it was possible to accurately determine whether CDK inhibitors bind irreversibly to CDK7, 12 or 13.
Experimental conditions and process: h3122 cells were cultured in vitro, grown to logarithmic growth phase, digested and collected cells, centrifuged at 1000rpm for 5min, the supernatant discarded, and the cell concentration was adjusted to 1X 10 6/mL. In a 12-well cell culture plate, 1ml of cells were added per well, 100nL of a DMSO solution (final concentration 1. Mu.M) of a representative drug at a concentration of 10mM was added per well, and the cells were incubated in a cell incubator (37 ℃ C., 5% CO 2) with THZ1, THZ531 or DMSO control for 4 hours, and then washed twice with a pre-chilled PBS solution, 200. Mu.L of NP40 cell lysate and a protease inhibitor were added to the wells, and lysed at 4 ℃ for 30 minutes. Lysates were collected, centrifuged at 15000rpm at 4℃for 15min, the supernatant was transferred to a sample tube, THZ1-biotin (final concentration 1. Mu.M) was added, and incubated at 4℃overnight. 10. Mu.L of streptavidin beads were added and allowed to bind for 2 hours at room temperature. After washing the microbeads with 1% NP40 cell lysate for 10 times, 20. Mu.L of 2% SDS lysate was added for lysis, and the mixture was boiled at 95℃for 10 minutes and loaded for western-blot identification.
FIG. 2 shows the competitive effect of representative compounds such as ZSQ-38, ZSQ8-36, etc. on covalent binding of THZ1-biotin to CDK7 or 12 in H3122 cells at a concentration of 1. Mu.M.
The experimental results show that:
THZ1 simultaneously inhibits covalent binding of THZ1-biotin to CDKs 7, 12 and 13; THZ531 has slight inhibition of CDK 7;
While ZSQ5-38, ZSQ-36, ZSQ9-75, ZSQ-22 and other compounds can completely or almost completely inhibit covalent binding of THZ1-biotin with CDK12 or 13 at a concentration of 1 mu M, but hardly affect covalent binding of THZ1-biotin with CDK7, ZSQ-38, ZSQ-8-36, ZSQ9-75, ZSQ-22 and other compounds have smaller effect on CDK7 and higher selectivity than THZ 531;
this demonstrates that ZSQ compounds are capable of highly potent, highly specific, irreversible inhibition of kinase activity of CDK12, 13 in cancer cells.
Activity test example 5 influence of CDK inhibitors on CDK7, 12 in vitro kinase Activity
Both CDK7 and 12 proteins catalyze the phosphorylation of the Ser5 site of Pol II CTD in vitro, and therefore, when the kinase activity of CDK7 or 12 is inhibited, the phosphorylation modification of the Ser5 site will be attenuated or lost.
Experimental conditions and process: after 293T cells overexpressed 3XFlag-CDK7 or 3X-Flag-CDK12 for 48 hours, they were washed twice with pre-chilled PBS solution, 1mL of RIPA buffer containing protease inhibitor was added and lysed at 4℃for 1 hour. The lysate was collected, centrifuged at 15000rpm at 4℃for 15min, the supernatant was transferred to a sample tube, 20. Mu.L of anti-Flag affinity gel was added, and incubated at 4℃overnight. The gel was washed 5 times with RIPAbuffer times and 3 times with a kinase buffer (50mM HEPES pH7.4, 50mM KCl,10mM MgCl 2), and 100. Mu.L of the kinase buffer was added and mixed well for the subsequent in vitro kinase reaction. mu.L of gel mixture was added to each well, and incubated overnight at 4℃at different concentrations of compound. Then 1. Mu.g of the purified GST-Pol II CTD protein expressed by the bacteria and 100. Mu.M ATP were added, and after 1 hour of shaking reaction at 37℃the reaction was terminated by adding 4%SDS loading buffer thereto, and the mixture was boiled at 95℃for 10 minutes, and the western-blot was identified.
FIG. 3 shows the effect of representative compounds such as ZSQ-36 and ZSQ-66 on CDK7 or 12 catalytic Pol II CTD Ser5 site phosphorylation modification at various concentrations.
The experimental results show that:
ZSQ5-38, ZSQ8-36 and other compounds can completely or almost completely inhibit CDK12 from catalyzing phosphorylation modification of Pol II CTD Ser5 site at low concentration, but do not influence CDK7 to catalyze phosphorylation modification of Pol II CTD Ser5 site, consistent with THZ531 phenotype;
in contrast, THZ1 inhibits both CDK7 and 12 catalytic substrate phosphorylation modifications;
ZSQ14-66 significantly inhibited the phosphorylation of both CDK7 and 12 catalytic substrates at 250nM concentration, while ZSQ-60 partially inhibited the phosphorylation of CDK7 catalytic substrates at 500nM concentration.
This suggests that a number of ZSQ compounds are capable of high-potency, specific kinase activity of CDK 12.
Activity test example 6 CDK Selectivity of inhibitors to kinase set
The adopted biological test scheme is as follows: effects of the compounds on the in vitro enzymatic activity of the kinase group.
To verify the selectivity of the compounds of the invention to the kinase group at the protein level, representative compounds ZSQ-36, ZSQ-36 were selected and the inhibition levels of the compounds on the phosphorylation of 370 kinase protein catalytic substrates were obtained using P 33 isotopically labeled ATP and radioactive kinase activity assay.
The method comprises the following steps: activity test of radioactive kinase group. The compound and the protein are mixed and pre-incubated for 1 hour at room temperature, then P 33 -ATP is added for reaction for 2 hours, the reaction mixture is spotted on P81 ion exchange chromatography paper, and the kinase activity is detected by a membrane filtration method. The final concentration of the compound was 1 μm and 2 replicates were used to calculate the dosing treatment group activity with 100% kinase activity for the single DMSO dosing group.
Table 4 CDK inhibitors selectivity for 370 different kinases
/>
/>
/>
/>
/>
/>
/>
As can be seen from table 4, the representative compounds inhibited the enzymatic activity of only a few kinases to below 50% at a concentration of 1 μm; in contrast, the representative compounds were able to completely inhibit kinase activity of CDK12 at a concentration of 500nM (Activity test example 5).
Studies show that THZ531 binds to different kinases at a concentration of 1. Mu.M as shown in Table 5, and the Score (Score) represents the percentage of protein not bound to the compound (i.e., protein with uninhibited kinase activity), and it can be seen that THZ531 binds strongly to kinases such as RSK2, STK16, etc., whereas the compounds of the invention have substantially no effect on the activity of these kinases, suggesting that the compounds of the invention have a different kinase set selectivity than the existing CDK12/13 inhibitors, possibly with better selectivity and safety in use.
TABLE 5
Pharmacokinetic properties of the Activity test example 7 CDK inhibitor
In this example, drug metabolism was tested in mice and the selectivity of the compounds of the invention for the kinase group was verified in vivo.
The method is as follows; compounds ZSQ-38, ZSQ-36 were selected and tested for their pharmacokinetic properties in mice (n=3) using a single administration of intraperitoneal injection (10 mg/kg).
Fig. 4 shows concentration time curves of representative compounds ZSQ-38 and ZSQ8-36 in plasma, as well as pharmacokinetic parameters.
The results showed that ZSQ-38 and ZSQ-36 peaked rapidly in mice after a single dose, and were able to stably maintain moderate drug concentrations, and exhibited long half-lives (17.3 and 9.8 for T 1/2 of ZSQ5-38 and ZSQ-36).
In addition, in the completed in vivo test, no obvious toxic or side effect was observed, nor was necrosis observed in normal tissues or cells of mice, suggesting that the compounds of the present invention have high safety.
Activity test example 8 CDK test of growth inhibitory Activity of inhibitors against various lung cancer cell lines with KRAS mutations
In this example, the growth inhibitory effect of representative compounds ZSQ-38 and ZSQ-36 of the present invention on lung cancer cell lines that either survive on the growth of the KRAS gene or have KRAS activating point mutations was demonstrated at the cellular level. 17 cells such as H441 and H460 are selected respectively, and the clone number of the cells is observed by a crystal violet staining means, so that the biological activity of the compound for inhibiting the growth of cancer cells is obtained.
The method comprises the following steps: after growing various lung cancer cells in vitro to logarithmic growth phase, the cells were digested and collected, centrifuged at 1000rpm for 5min, the supernatant was discarded, the cell concentration was adjusted to 1.5X10 5/mL, and the cells were inoculated into 12-well plates at 1mL per well. After 5 μl of each of the compounds or DMSO at different concentrations was added to the corresponding wells, the wells were incubated in a cell incubator (37 ℃ C., 5% CO 2) for one week (with medium change) and fixed for 20 minutes with 4% PFA solution added to each well, stained with 0.1% crystal violet solution for 20 minutes, washed twice with PBS, and scanned to give 100% cell viability for non-stimulated DMSO control wells.
FIG. 5 shows that representative compounds ZSQ-38 and ZSQ-36 were able to completely or effectively inhibit the growth and proliferation of most cell lines at a concentration of 1. Mu.M, and several cell lines such as SW1573, H460, etc. were able to completely or effectively inhibit the growth and proliferation at a concentration of 300 nM.
Discussion of the invention
Among the various proteins closely related to carcinogenesis, exacerbation, a number of members of the kinase protein family have been identified as effective therapeutic targets. Many of the identified or potential kinase targets have reactive sulfhydryl groups near their enzyme catalytic sites, thus providing the possibility for the development of covalent kinase inhibitors. Whereas CDKs 7, 12 and 13 in the cell Cycle Dependent Kinase (CDK) family are targets for this class of kinases.
The CDK (cyclin dependent kinases) family of kinases are ten or more members of the serine/threonine protein kinase family, some of which are key kinases involved in cell cycle regulation. Depending on the CDKs function, it can be divided into two main categories: CDKs 1,2, 4 and 6 are involved in cell cycle regulation; CDK7-13 is involved in transcriptional regulation.
CDK7-cyclin H, CDK8-cyclin C, CDK9-cyclin T and CDK12/13-cyclin K regulate initiation (initiation) or extension (elongation) of transcription by regulating phosphorylation of RNA polymerase II, which causes the latter to highly express various oncogenes (such as MYC, RUNX, etc.) via super-enhancer (super-enhancer), thereby maintaining growth and survival of cancer cells.
CDK12 is an important component for regulating DNA damage repair in cancer cells, and the inactivation of CDK12 can produce synergistic effect with DNA damage repair inhibitors (such as PARP inhibitor Olaparib), and can enhance infiltration of immune cells in solid tumors, thereby promoting curative effect of tumor immunotherapy.
CDK13 is a homologous protein to CDK12, with a structure very similar to CDK12, and only a few amino acid residues differ from CDK12, with known functions equivalent to CDK 12.
CDK7 is an important transcription factor that regulates the initiation of oncogene transcription, while regulating the normal operation of the cell cycle. The literature reports that inhibition of CDK7 may have an adverse effect on the differentiation of normal cells.
The present invention provides compounds of formula I that selectively inhibit CDK12 and/or 13, while having no or weak inhibition of CDK 7. Studies have shown that inhibition of CDK7, 12, 13 simultaneously blocks activation and extension of transcription simultaneously, whereas inhibition of CDK12, 13 alone affects only extension of the transcription process. While inhibiting multiple CDKs has greater side effects on normal cell growth survival. For cancer cells, which are generally inherently genetically unstable and more dependent on the mechanism of DNA damage repair, selective inhibition of CDKs 12, 13 is sufficient to promote apoptosis in tumor cells.
On the other hand, the existing CDK7/12/13 triple inhibitor THZ1 inhibits not only the three CDKs but also many other kinases, thereby causing toxic and side effects; the modified SY-1365 mainly inhibits CDK7, and has weak inhibition effect on CDK12 and 13; whereas dual inhibitors of CDK12/13, which do not inhibit or substantially inhibit CDK7, have significantly better targeting selectivity than triple inhibitors (see activity test example 6), tumors of different genetic subtypes are also sensitive to them differently than CDK7 inhibitors.
The CDK inhibitor disclosed by the invention is a target inhibitor obtained in an optimized way, and in the structure of the compound disclosed by the invention, an organic arsine group (moeity) is a part which is subjected to covalent action with an active site of CDK12/13, so that excellent inhibitory activity and better specificity can be provided, and from experimental data, the CDK inhibitor disclosed by the invention specifically binds to specific kinases such as CDK12, CDK13 and the like, does not bind or basically does not bind to CDK7 or other 300 kinases tested, and has good selectivity among different cell lines, so that the safety of arsine compounds is far better than that of the prior arsine compounds.
All documents mentioned in this disclosure are incorporated by reference in this disclosure as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the application as defined in the appended claims.
Claims (10)
1. A compound of formula I, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof;
Wherein,
For/>
R 3 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl;
n 1 is 1 or 2;
Each R 4 is independently selected from: H. d, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy;
L 1、L2 and L 3 are each independently selected from the group consisting of: none, - (Z) m-; and L 1 and L 2 are not both absent; wherein each Z is independently selected from: C1-C6 alkylene, -NR 6-,-NR6-R7 -, m is 1,2,3 or 4;
Each R 6 is independently selected from the group consisting of: H. a substituted or unsubstituted C1-C4 alkyl group;
r 7 is a substituted or unsubstituted C1-C8 alkylene group;
a is selected from the group consisting of: an unsubstituted, substituted or unsubstituted phenyl group, a substituted or unsubstituted C3-C6 cycloalkyl group, a substituted or unsubstituted 3-6 membered heterocycloalkyl group;
b is selected from the group consisting of: substituted or unsubstituted 5-10 membered heteroaryl;
C is selected from the group consisting of: a substituted or unsubstituted phenyl group, a substituted or unsubstituted 5-10 membered heteroaryl group, a substituted or unsubstituted 3-10 membered heterocycloalkyl group;
wherein the term "substituted" refers to a group wherein a hydrogen atom is replaced with one or more substituents selected from the group consisting of: halogen, deuterated, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C1-C6 alkyl S (=o) 2 -, oxo (=o), -CN, -OH, carboxyl, or substituted C1-C6 alkyl and said substituents are selected from the group consisting of: oxo, -CN, -NH 2, -OH, C2-C6-amide.
2. The compound of claim 1, wherein R 3 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl; by "substituted" is meant that a hydrogen atom on the group is replaced by one or more substituents selected from the group consisting of: halogen, deuterated, C1-C6 alkyl;
n 1 is 1 or 2;
Each R 4 is independently selected from: H. d, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy;
L 1、L2 and L 3 are each independently selected from the group consisting of: none, - (Z) m-; and L 1 and L 2 are not both absent; wherein each Z is independently selected from: C1-C6 alkylene, -NR 6-,-NR6-R7 -, m is 1,2,3 or 4;
Each R 6 is independently selected from the group consisting of: H. unsubstituted C1-C4 alkyl;
R 7 is unsubstituted C1-C4 alkylene;
A is selected from the group consisting of: unsubstituted phenyl, unsubstituted cyclohexyl, unsubstituted piperidinyl;
B is selected from the group consisting of: substituted or unsubstituted pyrimidinyl or pyrazolopyrimidinyl, said "substitution" meaning that a hydrogen atom on the group is substituted with one or more substituents selected from the group consisting of: halogen, deuterated, C1-C6 alkyl;
C is selected from the group consisting of: substituted or unsubstituted phenyl, substituted or unsubstituted indolyl, substituted or unsubstituted piperidinyl; by "substituted" is meant that a hydrogen atom on the group is replaced by one or more substituents selected from the group consisting of: halogen, deuterated, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkyl S (=O) 2 -, -OH substituted C1-C6 alkyl.
3. A compound according to claim 1 wherein,At positions 2, 3 or 4.
4. The compound of claim 1, wherein the compound of formula I has the structure of I-a:
5. the compound of claim 1, wherein the compound of formula I is selected from the following table:
6. A pharmaceutical composition, characterized in that the pharmaceutical composition comprises;
(a) A therapeutically effective amount of a compound of formula I as defined in claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
7. Use of a compound of formula I as defined in claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined in claim 6, for the manufacture of a pharmaceutical composition for the treatment and/or prophylaxis of a disease or condition associated with CDK12 and/or CDK13 activity or expression.
8. The use according to claim 7, wherein the disease or condition is cancer.
9. A process for the preparation of a compound of formula I according to claim 1, comprising the steps of:
(a) Reacting the compounds of formula A4 and formula A5 in an inert solvent to form a compound of formula I:
In the method, in the process of the invention,
Z is selected from: halogen, -OMs, -Ots, -Otf, -Oac or-OAr;
X1、X2、R1、R2、R3、R4、L1、L2、L3、A、B、C、 And n1 is as defined in claim 1.
10. A CDK12 and/or CDK13 inhibitor comprising:
A compound of formula I according to claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 6.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910925781.8A CN112574255B (en) | 2019-09-27 | 2019-09-27 | Organic arsine-based CDK inhibitor and preparation method and application thereof |
PCT/CN2020/117550 WO2021057867A1 (en) | 2019-09-27 | 2020-09-24 | Class of cdk inhibitor based on organic arsine, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910925781.8A CN112574255B (en) | 2019-09-27 | 2019-09-27 | Organic arsine-based CDK inhibitor and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112574255A CN112574255A (en) | 2021-03-30 |
CN112574255B true CN112574255B (en) | 2024-05-10 |
Family
ID=75110101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910925781.8A Active CN112574255B (en) | 2019-09-27 | 2019-09-27 | Organic arsine-based CDK inhibitor and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112574255B (en) |
WO (1) | WO2021057867A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113801163A (en) * | 2020-06-17 | 2021-12-17 | 中国科学院上海有机化学研究所 | II-type pyruvate kinase inhibitor based on organic arsenic and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2772303A (en) * | 1947-01-28 | 1956-11-27 | Ernst A H Friedheim | Therapeutic organometallic compounds containing antimony and sulfur |
CN1589149A (en) * | 2001-09-24 | 2005-03-02 | 托斯克公司 | Reduced toxicity cisplatin formulations and methods for using the same |
WO2005034935A1 (en) * | 2003-10-10 | 2005-04-21 | Assistance Publique - Hopitaux De Paris | Use of organoarsenic or organoantimony derivatives for their anticancer properties |
CN103756630A (en) * | 2014-01-09 | 2014-04-30 | 浙江新安化工集团股份有限公司 | Single-component moldproof transparent dealcoholized silicone sealant and preparation method thereof |
CN107814796A (en) * | 2017-10-16 | 2018-03-20 | 湖南大学 | A kind of environment sensitive dyestuff based on benzofuraxan and its preparation method and application |
CN109369724A (en) * | 2018-10-23 | 2019-02-22 | 兰州大学 | A kind of organoarsenium compound and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002952526A0 (en) * | 2002-11-07 | 2002-11-21 | Unisearch Limited | Induction of the mitochondrial permeability transition |
-
2019
- 2019-09-27 CN CN201910925781.8A patent/CN112574255B/en active Active
-
2020
- 2020-09-24 WO PCT/CN2020/117550 patent/WO2021057867A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2772303A (en) * | 1947-01-28 | 1956-11-27 | Ernst A H Friedheim | Therapeutic organometallic compounds containing antimony and sulfur |
CN1589149A (en) * | 2001-09-24 | 2005-03-02 | 托斯克公司 | Reduced toxicity cisplatin formulations and methods for using the same |
WO2005034935A1 (en) * | 2003-10-10 | 2005-04-21 | Assistance Publique - Hopitaux De Paris | Use of organoarsenic or organoantimony derivatives for their anticancer properties |
CN103756630A (en) * | 2014-01-09 | 2014-04-30 | 浙江新安化工集团股份有限公司 | Single-component moldproof transparent dealcoholized silicone sealant and preparation method thereof |
CN107814796A (en) * | 2017-10-16 | 2018-03-20 | 湖南大学 | A kind of environment sensitive dyestuff based on benzofuraxan and its preparation method and application |
CN109369724A (en) * | 2018-10-23 | 2019-02-22 | 兰州大学 | A kind of organoarsenium compound and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN112574255A (en) | 2021-03-30 |
WO2021057867A1 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2833576T3 (en) | Novel glutaminase inhibitors | |
KR101297497B1 (en) | Protein kinase inhibitors | |
AU2015407300B2 (en) | 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof | |
KR20100016431A (en) | Pharmaceutical compounds | |
CN111153899A (en) | Substituted pyridine compound, preparation method and application thereof | |
AU2013272701A2 (en) | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | |
WO2007042810A1 (en) | Pyrimidine derivatives for the treatment of cancer | |
CN106810536A (en) | A kind of kinases inhibitor and preparation method thereof and medical usage | |
WO2014040549A1 (en) | Alkynyl heteroaromatic ring compound and application thereof | |
KR20220028072A (en) | Heterocyclic compounds as BET inhibitors | |
JP2020506957A (en) | Imidazopyrazine compounds, their production methods and applications | |
EP3694330B1 (en) | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
CN113683616A (en) | KRAS G12C mutein inhibitors | |
CN112110938B (en) | Compound as protein kinase inhibitor and preparation method and application thereof | |
JP2011530574A (en) | 2-alkyl-6-cycloamino-3- (pyridin-4-yl) imidazo [1,2-IB] pyridazine derivatives, their preparation and therapeutic application | |
AU2017265769B9 (en) | Novel 5H-Pyrrolo(2,3-D)Pyrimidin-6(7H)-one derivative | |
CA2553243C (en) | Pyrrolo pyrimidine derivatives useful for treating proliferative diseases | |
CN112574255B (en) | Organic arsine-based CDK inhibitor and preparation method and application thereof | |
JP6457523B2 (en) | Sulfoxyimine substituted quinazolines for pharmaceutical compositions | |
CN117729921A (en) | Compounds and methods as PD1/PD-L1 inhibitors | |
EP2919782A1 (en) | Secondary alcohol subsituted triazoles as pde10 inhibitors | |
EP4249489A1 (en) | Heterocyclic compound as diacylglycerol kinase inhibitor and use thereof | |
CN103059002A (en) | Pyrimidine derivative with Aurora kinase inhibitory activity and preparation method and application thereof | |
CN113563341B (en) | Substituted pyrazolo [1,5-a ] pyrimidine compounds as Trk inhibitors | |
CN111170996B (en) | Pyrimidine derivative with ALK inhibitory activity and synthetic method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |